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aHUS – recurrent atypical haemolytic uremic syndrome 
AMD – age-related macular degeneration 
ANOVA - analysis of variance  
AP – alternative pathway 
APC – antigen presenting cell 
AU - arbitrary units  
Basic FGF - fibroblast growth factor 
C1-INH - C1-inhibitor  
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CP – classical pathway 
CyP – cyanobacterial product 
DAMPs – damage/danger associated molecular patterns 
ECD - extracellular domain  
ECMO - extracorporeal membrane oxygenation 
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EIAs - enzyme immunoassays  
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FDC - follicular dendritic cell 
FiO2  - fraction of inspired oxygen   
GA – gestational age 
G-CSF - granulocyte colony-stimulating factor  
GM-CSF - granulocyte macrophage colony-stimulating factor 
HFV – high frequency ventilation 
IgG - immunoglobulin G  
IL – interleukin 
ILCOR – The International Liaison Committee on Resuscitation  
IFN- - interferon-gamma 
IP-10 - interferon-inducible protein 
LP – lectin pathway 
LPS - lipopolysaccharide 
mAb - monoclonal antibody  
MASP - mannose binding lectin associated protease 
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MAS - meconium aspiration syndrome 
MASF - meconium-stained amniotic fluid 
MBL - mannose binding lectin 
MCP-1 - monocyte chemotactic protein-1 
MD-2 – myeloid differentiation protein-2 
MIP-1 - macrophage inhibitory protein-1 
MPGN – membranoproliferative glomerulonephritis 
NCPAP – nasal continuous positive end-expiratory airway pressure 
NF-B - nuclear factor kappa-light-chain enhancer of activated B-cells 
NHS – normal human serum 
NLRs – NOD-like - nucleotide-binding oligomerization-domain protein like receptors 
NO – nitrogen oxide 
NPS - normal pig serum 
OI – oxygenation index 
PAMPs - pathogen associated molecular patterns 
PBS - sterile phosphate-buffered saline 
PDGFbb - platelet derived growth factor bb 
PEEP – positive end expiratory pressure 
PIP - peak inspiratory pressure 
PLD – partial lipodystrophy 
PPHN – persistent pulmonary hypertension of the newborns 
PRR – pathogen recognition receptor 
RANTES - regulated upon activation, normal T cell expressed and secreted 
ROS – reactive oxygen species 
RLRs - RIG-1-like receptors  
SLE – systemic lupus erythematosus 
TCC - terminal sC5-9 complement complex  
TIR - TOLL/IL-1 receptor   
TLR - toll like receptor 
TNF- - tumor necrosis factor alpha 
VCP- vaccinia complement control protein  
VEGF - vascular endothelial growth factor 
VI – ventilation index 
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2 INTRODUCTION  
2.1 Definitions
Meconium aspiration syndrome (MAS) is defined according to Cleary and Wiswell as 
“respiratory distress in an infant born through meconium-stained amniotic fluid 
(MSAF) whose symptoms cannot otherwise be explained” (1). Severe MAS is 
classified as cases that need mechanical ventilation. 
2.2 Epidemiology
In the developed world, the incidence of MAS is low, in UK about 2 per 1000 live 
births (2). This incidence is considerably higher in the developing world, 4-11 per 
1000 in South Africa (3). In a cohort of 176 000 neonates born from 1973-1987, 
Wiswell reported an overall frequency of MASF in 12.5% of all deliveries. Of those 
born through MASF, approximately 2-5% developed MAS and more than 4 % of 
them died (4). In a cohort from Australia and New Zealand (1995-2002) the incidence 
of severe MAS was 0.43 per 1000 live births (5). There was an overall decrease in the 
incidence to 0.35 per 1000 in 2002. Between 36 and 40 weeks gestational age (GA), 
the incidence varied between 0.24-0.46 per 1000 compared to an incidence of 1.42 per 
1000 at 42 weeks and beyond. Mortality in the severe MAS cohort was 2.5%. Yoder 
et al reported a decreased incidence of MAS from 5.8% (1990-1992) to 1.5 % (1997-
1998) in meconium-stained infants >37 weeks in a prospective study (6). Significant 
changes in obstetrical characteristics were reported, but the only change in neonatal 
characteristics was a 33% decrease in births > 41 weeks. 
2.3 Etiology
Aspiration of meconium was earlier considered to be a postnatal event caused by 
aspiration of meconium at the first breath (7). Suction of the trachea and oropharynx 
at delivery decreased the incidence of mild and moderate MAS (8;9). MAS is no 
longer considered to be a postnatal disorder caused by postnatal aspiration, but rather 
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a disorder with antepartum, intrapartum and neonatal causes (10). Now, the 
hypothesis is that aspiration of meconium may occur in utero, during or after delivery, 
and that a chronic in utero insult may be responsible for severe MAS (11;12). Thureen 
et al found that in eight autopsies, pulmonary and placental changes suggesting in
utero onset of  a disease with subacute or chronic duration (13). This in concordance 
with the observed effects by Wiswell et al showing no effect on the incidence of MAS 
if the infant was intubated and tracheal suction performed  in the delivery room, 
compared to infants only treated if they developed symptoms (14). Vain et al showed 
that routine intrapartum oropharyngeal and nasopharyngeal suctioning of term-
gestation infants born through MSAF did not prevent MAS (15).  
Ghidini et al reviewed the literature and concluded that severe MAS is caused by 
chronic asphyxia or intrauterine infection (12).  
 
2.4 Pathophysiology
MAS has a complex not well defined pathophysiology (1). Several factors are 
involved including (1) direct toxicity of meconium and its constituents resulting in 
alveolar and parenchymal inflammation with release of inflammatory mediators, 
edema and protein leakage into the alveoli, tissue necrosis and apoptosis in the lung 
and ulcerations of the umbilical cord, (2) airway obstruction  caused by meconium, 
edema fluid, protein exudates and blood cells (3) altered elastic forces in the lungs 
resulting in increased resistance and decreased compliance, (4) inactivation and 
dysfunction of surfactant caused by meconium, protein and inflammatory cells 
leading to atelectases, air trapping, pneumothorax, right-to-left shunting, (5) in utero 
hypoxemia leading to pulmonary vascular remodelling and lung parenchymal 
changes, and vasoconstriction of placental and umbilical vessels. Ventilation-
perfusion mismatch contribute further to acidosis, hypercapnia, and hypoxemia. 
 
Meconium-stained amniotic fluid is rarely detected before 37 weeks of gestation (16), 
but occurs in more than one third of pregnancies lasting longer than 42 weeks (17). 
Prenatal passage of meconium is normally prevented by lack of intestinal peristalsis 
caused by low motilin levels (18), tonic contraction of the anal sphincter and a 
terminal cap of viscous meconium. 
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Intrauterine infections may induce a fetal inflammation syndrome with activation of 
neutrophils, macrophages, cytokines and the complement system, resulting in tissue 
destruction. The incidence of clinical chorioamnionitis is significantly higher in the 
presence of  severe than mild MAS (19). Among women in preterm labor, the 
prevalence of positive amniotic fluid cultures after amniocentesis is significantly 
higher in those with MASF compared to those with clear fluid (20). Histological 
evidence of acute placental inflammation is present in a majority of cases of severe 
MAS (21), supporting the fact that intrauterine infections may underlie or contribute 
to a proportion of cases of severe MAS. This is supported by the lack of studies that 
directly correlate the severity of MAS with the amount of meconium aspirated, the 
thickness of meconium, and the duration of the exposure to meconium (22). 
 
The fact that the incidence of severe MAS is higher in post-term infants (RR= 3.1; 
95% CI, 2.6-3.7) (23), that placental ischemic changes suggesting long compromise of 
utero-placental bloodflow (13), that pulmonary vascular hypertrophy found in almost 
all cases of severe MAS also may be found in the absence of meconium passage (24), 
and that chronic in utero hypoxia may lead to persistent pulmonary hypertension of 
the newborns (PPHN) also in cases without meconium passage (24), supports that 
severe MAS may be caused by chronic asphyxia. 
 
2.4.1 Meconium
Meconium is detected in the gastrointestinal tract of the fetus as early as 10-16 weeks 
of GA and represents material accumulated during fetal life. It is blackish-green, 
odourless and varies in amount from 60 to 200g (25). Meconium consists of 72-80% 
water (26). Meconium contains secretions from salivary and intestinal glands like 
mucus, bile and bile acids, fatty acids and steroids from the gut, cellular debris, 
lanugo hair, components of vernix caseosa, amniotic fluid, and blood (27). Meconium 
may also contain various amounts of proinflammatory substances including TNF-, 
IL-1, IL-6 and especially IL-8 (28).  
 
Meconium and amniotic fluid have been considered to be sterile as well as the 
gastrointestinal tract of the normal fetus (29). Yet the prevalence of positive amniotic 
fluid cultures was significantly higher in women with meconium-stained amniotic 
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fluid and intact membranes than in women with clear fluid (20). Meconium may 
contain variable amounts of lipopolysaccharide (LPS) under certain conditions. First, 
meconium from normal deliveries may be contaminated by LPS during collection and 
preparation, influencing the results from in vitro and in vivo experimental studies 
using normal meconium. Second, fetal membranes, even from deliveries by cesarean 
section at term, had microbial organisms present (70%) although only less than 25% 
showed inflammatory cells present (30). Third, intrauterine infections may increase 
bacterial and LPS load. Fetal membranes obtained after premature labor or after 
prolonged premature rupture of membranes are mainly positive for bacteria deep 
within the membranes and for inflammatory cells in amnion or chorion (30). Jimenez 
et al identified Enterococcus fecalis in 17 of  21 meconium samples from healthy 
newborns and Staphylococcus epidermidis in 10 of the samples (31). Escherichia coli 
and Enterobacter spp. were also detected. Labelled E.fecium given orally to pregnant 
mice was isolated from aseptically collected meconium from fetuses delivered by 
cesarean section one day before predicted labor. Meconium has extremely high 
surface tension (32). In vitro meconium is chemotactic to neutrophils (33) and 
possibly also vasoactive (34). 
 
2.4.2 Lungs and vessels
Respiratory symptoms may be secondary to meconium aspiration in utero or at birth, 
or to alterations in the pulmonary vasculature secondary to asphyxia or to meconium 
itself (26). MAS is believed to be caused by a combination of mechanical blockage of 
the small airways and chemical pneumonitis induced by meconium particles aspirated 
(24;35). Aspiration of meconium may cause partial obstruction of the airways with air 
trapping and atelectases and development of air leaks or complete obstruction with 
alveolar collapse and ventilation-perfusion mismatch (36). Estimated risk of 
pneumothorax is 15-33% (1). Mechanical dysfunction of lungs is more severe during 
the early phase of MAS with lower dynamic and specific lung compliance and 
increased airway resistance (37). 
 
Vasospasms, hypertrophy of the pulmonary musculature, and pulmonary hypertension 
lead to right-to-left shunting through the foramen ovale and ductus arteriosus. MAS is 
the most common cause of persistent pulmonary hypertension of the newborns 
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(38;39) with abnormally constricted pulmonary vasculature. About two thirds of 
infants with PPHN have meconium-stained amniotic fluid and about half of the 
infants with PPHN have the concurrent diagnosis of meconium aspiration syndrome. 
Meconium injury trigger postnatal release of vasoactive mediators like endothelin-1, 
thromboxane-A2 and prostaglandin E2 (40;41). Meconium induced a dose-dependent 
oxidative burst in neutrophils with increased levels of vasoactive peptides (42;43).  
2.4.3 Surfactant displacement and inactivation 
Meconium, protein, and inflammatory cells inactivate surfactant function and alters 
surfactant production (44-46). Meconium displaces surfactant from the alveolar 
surface and inhibits surfactant function reducing its ability to reduce the surface 
tension. Bronchial lavage fluid from infants with MAS, contained increased levels of 
albumin, total protein and membrane-derived phospholipids compared to controls. 
The inhibition of surfactant in the alveolar spaces may be mediated by meconium, 
plasma proteins, edema fluid and haemoglobin. 
 
2.4.4 Meconium aspiration syndrome and inflammation 
Toxic effects of meconium trigger inflammation in the lungs (39;47). Activated 
neutrophils and macrophages are detected in the lung parenchyma and alveoli only 
hours after meconium aspiration (48).  Meconium activates the complement system 
both in vitro (49) and in vivo in an experimental model of MAS in newborn pigs (50). 
The latter is associated with a systemic inflammatory response with increased 
formation of proinflammatory cyokines. The release of proinflammatory cytokines 
may directly injure the lung parenchyma resulting in vascular leakage causing 
pneumonitis and pulmonary edema (51;52). Most proinflammatory cytokines and 
chemokines measured, as well as the anti-inflammatory cytokine IL-10, were 
significantly elevated in sera from neonates with MAS (53). 
 
Meconium-induced inflammatory lung injury is associated with respiratory epithelial 
apoptosis in several animal models (52;54). Meconium activates the pulmonary renin-
angiotensin system shown by an increase in angiotensinogen mRNA associated with 
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apoptosis and cytokine release. Angiotensin-II receptor, which is expressed in several 
cell types in the newborn lung, including bronchial and alveolar epithelium and 
bronchial and vascular smooth muscle, are up-regulated after meconium exposure 
(55).  
2.5 Risk factors 
Signs of fetal compromise like abnormalities of fetal heart tracings and/or low Apgar 
scores increase the risk of MASF (56) and of MAS in the meconium stained infant 
(6). However, normal acid-base status at delivery is present in many cases of severe 
MAS, suggesting that either a pre-existing injury or nonhypoxic mechanisms also 
must be involved (11).  
 
There is an increased risk of MAS in Africans (57)  and Pacific Islanders (58), and 
also in afro-Americans compared to other Americans.  
 
Advanced gestation is a risk factor of both MASF and MAS (17). Risk factors for 
developing respiratory distress in infants born through meconium-stained amniotic 
fluid are male gender, few prenatal visits, abnormal fetal heart tracing, 
oligohydramnios, cesarean delivery, and low Apgar score (59)   
2.6 Prenatal management 
Transcervical intrapartum infusion of saline into the amniotic cavity has been 
proposed to reduce the risk for MAS. The proposed mechanism is mechanical 
cushioning of the umbilical cord to prevent recurrent umbilical compressions leading 
to fetal acidosis and dilution of meconium to reduce mechanical and inflammatory 
effects (60). A systematic review of the literature by Xu concluded that only in 
settings with limited peripartum surveillance and where complications are common, 
amnioinfusion appeared to reduce the risk of MAS (60).  
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2.7 Delivery room management 
Carson at al demonstrated in 1976, a decreased incidence of MAS after intrapartum 
oropharyngeal suction, that is suction after delivery of the head (61). Vain et al 
showed that routine intrapartum oropharyngeal and nasopharyngeal suctioning of 
term-gestation infants born through MSAF did not prevent MAS (15). Wiswell et al 
showed no effect on the incidence of MAS if the infant was intubated and tracheal 
suction performed  in the delivery room, compared to infants only treated if they 
developed symptoms (14). Routine intrapartum oropharyngeal and nasopharyngeal 
suctioning of term-gestation infants born through MSAF or routine endotracheal 
intubation at birth in vigorous meconium-stained babies, is not recommended 
(14;15;47;62). 
 
Still the the International Liaison Committee on Resuscitation (ILCOR) recommends 
tracheal suction of the depressed meconium-stained infant immediately post-partum 
and before stimulation, although this is not evidence-based. 
2.8 Treatment 
Infants at risk for MAS with respiratory distress must be monitored closely and 
supportive treatment must be provided if necessary. In the Australian /New Zealand 
cohort there was an increasing use of surfactant, high frequency ventilation (HFV) 
and inhaled Nitric Oxide from 1995-2002 (5). However, the amount of infants who 
needed to be put on extracorporeal membrane oxygenation (ECMO) (1.1%) did not 
change during the study period. 
 
The amount of ventilatory support needed, depends on the amount of respiratory 
distress. Some infants only need oxygen, some nasal continuous positive end-
expiratory airway pressure (NCPAP). HFV treatment minimizes barotraumas. HFV 
improved oxygenation in an experimental model of MAS in rats especially when 
combined with surfactant (63). Carter et al investigated rescue with HFV in ECMO 
candidates in newborns with respiratory distress. Almost 50% responded to HFV 
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alone, but amongst the non-responders there were a lot of infants with MAS (64). 
Experimental data suggest that HFV is an effective ventilator mode to improve gas 
exchange in MAS. 
2.8.1 Surfactant
Bolus surfactant therapy has been studied in several animal and human models. Two 
randomized controlled trials of bolus surfactant have been conducted (65;66). The 
studies were different, but data from both studies pooled together, suggest that 
surfactant in repeated doses in ventilated infants with MAS, may be associated with a 
reduction in the need for ECMO.  
 
Therapeutic lung lavage has been thoroughly investigated in several animal models. 
Few human randomized controlled studies are yet published. Saline, perfluorocarbon, 
full-strength and diluted surfactant are lavage fluids used in animal studies (67). Lung 
lavage using surfactant improved gas exchange compared to bolus surfactant. 
Oxygenation seemed to improve and the incidence of pneumothorax seemed reduced 
in some studies (67). The only prospective randomized controlled trial performed by 
Wiswell et al enrolling 22 infants, found no clear differences between lavaged 
individuals and controls in terms of air leak, duration of ventilation, and the need for 
ECMO (68). 
 
 A Cochrane review published in 2007 concludes that surfactant administration may 
reduce the severity of respiratory illness and decrease the number of infants with 
progressive respiratory failure requiring support with ECMO, but the relative efficacy 
of surfactant therapy compared to or in conjunction with other approaches to 
treatment, including inhaled nitric oxide, liquid ventilation, surfactant lavage and high 
frequency ventilation remains to be tested (69). 
2.8.2 Steroids
Animal studies with corticosteroids have shown promising results (70;71). A 
Cochrane review of two small randomized controlled trials failed to demonstrate 
 19
improved outcome in duration of ventilation, air leaks or mortality (72). Infants 
treated with corticosteroids actually required supplemental oxygen therapy for a 
longer period. Salvia-Roigés combined surfactant lavage with dexamethasone in a 
small human study. Oxygenation significantly improved (73). TNF- levels in 
tracheal aspirates were suppressed with use of steroids in newborns with MAS (74) . 
 
2.8.3 Immunoglobulins
Intravenous immunoglobulins in a pig-model of MAS improved pulmonary 
hypertension and oxygenation, but in lung tissue of animals pre-treated with 
immunoglobulins, neutrophil accumulation was increased (75). 
2.8.4 Other
Pre-treatment with captopril, an angiotensin converting enzyme inhibitor,  
significantly inhibited meconium-induced lung cell death and cytokine expression in 
newborn rabbit lungs (76;77). Addition of hyaluron, a substance natural occurring in 
alveolar fluid, to surfactant improved surface tension in the alveoli of rats in the 
presence or absence of meconium (78). CC10, clara cell protein is an anti-
inflammatory agent that may inhibit phospholipase A2. CC10 reduced the amount of 
TNF- in bronchial lavage fluid in an experimental model of MAS in pigs (79).  
2.9 Innate immunity and inflammation 
Innate immunity is an ancient form of host defence against infection and danger 
signals and exists probably in all multicellular organisms (80). The innate immune 
system is also involved in several normal physiological processes like tissue 
remodelling during development and after damage, transport of blood lipids, and 
scavenging of apoptotic cells (81). Macrophages, dendritic cells, polymorph nuclear 
leukocytes and humoral factors like complement proteins, coagulation factors and 
collectins recognizes tissue-derived signals as well as pathogens. Innate immunity 
recognition is mediated by receptors which specificity is genetically predetermined. 
The innate immune system recognizes highly conserved structures present on large 
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numbers of microorganisms referred to as pathogen-associated molecular patterns 
(PAMPs) (82). That is bacterial LPS, peptidoglycan, lipothecoic acids, mannan, 
zymosan, double stranded RNA, bacterial DNA, and glucans (82). Host-derived 
immunostimulators like hyaluronon, heat-shock proteins, surfactant proteins, IFN-, 
uric acid, fibronectin, -defensin and cardiolipin also signal through the same 
receptors as PAMPs, originally termed damage-associated molecular patterns 
(DAMPs) (81;83). Recent years has the abbreviation DAMP, alternatively been used 
as “danger-associated molecular patterns”, covering danger signalling of both 
endogenous and exogenous ligands. 
 
The pattern-recognition-receptors (PRRs) are expressed on many effector cells of the 
innate immune system as macrophages, dendritic cells and B cells (80) and also on 
most non-immune innate cells like epithelial cells. PRRs and soluble pattern 
recognition molecules are innate sensors that discriminate self from non-self and 
damaged or modified self, and link innate to adaptive immunity (84). The effector 
cells are triggered immediately to perform their specific response as soon as the 
PAMP binds to the receptor. PRRs are involved in internalization of microbes by 
phagocytes (soluble PRRs and endocytic receptors), cell activation (signalling PRRs) 
and also recognition of dying cells (i.e. modified self) (84).  PRRs are typically Toll-
like receptors (TLRs), nucleotide-binding oligomerization-domain protein like 
receptors (NOD-like receptors (NLRs)), and RIG-1-like receptors (RLRs), whereas 
soluble recognition molecules include collectins like mannose-binding lectin (MBL), 
ficolins, C-reactive protein (CRP), C1q, and natural immunoglobin M (IgM) (85). 
MBL is a well known recognition molecule. It is a calcium-dependent lectin which 
binds microbial carbohydrates to initiate the lectin pathway of complement activation. 
It may bind to carbohydrates on Gram-positive and Gram-negative bacteria, yeast and 
some viruses and parasites (86). Recognition molecules mediate microbial 
opsonisation, complement activation and phagocytosis (87).  
 
The TLRs belong to a family of type 1 transmembrane glycoproteins that recognizes 
structural patterns on bacteria, fungi, and viruses (87). The complement system and 
TLRs, including the CD14-associated TLR4/MD-2 complex, are two important 
components of the innate immune system, which both act upstream and partly 
independently (88). They recognize exogenous and endogenous ligands. Recent 
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studies have suggested several cross-talk mechanisms between the two systems (89). 
Activation of C3a and C5a receptors enhanced the TLR-induced formation of 
proinflammatory cytokines in mice (90).  Complement and TLRs are also important 
regulators of adaptive immunity (91;92). 
 
An inflammatory response triggered by infection or tissue injury results in the 
delivery of blood components (plasma and leukocytes) to the site of infection or 
injury (93). In bacterial infections receptors of the innate immune system (TLRs and 
NLRs) are triggered (94). An initial recognition of the infection is mediated by tissue-
resident macrophages and mast cells and results in the formation of several 
inflammatory mediators including chemokines, cytokines, vasoactive amines, 
eicosanoids, and products of proteolytic cascades. They elicit an inflammatory exudat 
locally. Plasma proteins and leukocytes, normally restricted to blood vessels, gain 
access. The activated endothelium allows selective extravasation of neutrophils which 
attempt to kill invading agents by releasing toxic content in their granules including 
reactive oxygen species (ROS), reactive nitrogen species, proteinase 3, cathepsin G 
and elastase (95). Collateral damage to host tissue is unavoidable. A successful 
inflammatory response results in elimination of the infectious agent followed by a 
repair and resolution phase. A controlled inflammatory response is beneficial, but may 
become detrimental if deregulated. 
  
2.9.1 The complement system 
The complement system is an important part of innate immunity. It defends the 
organism against pyogenic bacterial infections, bridges innate and adaptive immunity 
and disposes immune complexes and other products of inflammation (96).  
The complement system consists of more than 30 different proteins in plasma or on 
cell surfaces and act as a cascade system of proteases. The complement system has 
three activating pathways; the classical pathway (CP), the lectin pathway (LP) and the 
alternative pathway (AP). Activation of all pathways result in cleavage of C3, but the 
initial activation of each pathway is unique.  
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Fig 1: The complement system (Haboe M, Mollnes TE 2008, J .Cell. Mol. Med 12; 
1074-83, with the permission of Blackwell Publishing Ltd) 
 
 
The classical pathway is activated when C1q reacts with antibodies bound to their 
antigens, but may also react with other agents like C-reactive protein (CRP), SIGN-
R1 and phosphatidylserine (97). C1s then cleaves C4 to C4b which  binds covalently 
to the bacterial surface and then cleaves C2 leading to the formation of the C3 
convertase of the classical pathway, C4b2a (96). C4b2a cleaves C3 to C3b to form the 
C5 convertase C4b2a3b. 
 
The lectin pathway is activated when MBL or ficolines recognizes carbohydrate 
structures on microbial surfaces and other sugars like N-acetyl-D-glucosamine 
(98;99). LP may also be activated by IgA and by structures on damaged endothelium 
(100). The MBL-associated serine proteases (MASPs) are triggered. MASP-2 leads to 
the formation of the LP convertase C4b2a, while MASP-1 under certain conditions 
may cleave C3 directly (96).  
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The alternative pathway is initiated by the covalent binding of a small amount of C3b 
to hydroxyl groups on cell-surface carbohydrates and proteins, by foreign surfaces 
and also spontaneously by hydrolysis of the internal C3 thioester bond (96;101;102). 
C3b binds factor B and forms the C3bB complex. Factor D then cleaves factor B to 
form the alternative pathway convertase, C3bBb (96). Properdin, the only known 
regulator of complement that amplifies activation, stabilizes the C3bBb complex 
enhancing AP activation, but acts also as a recognition factor directly initiating AP 
activation (103). AP amplification plays an important role for the final effect of initial 
activation of CP and LP (101;104).  
 
The C3 convertases then cleave C3. C3b binds covalently to the site of the 
complement activation, leading to the formation of C5 convertases. The C5 
convertases then cleave C5. C5b initiates the formation of the C5b-9 terminal 
complement complex (TCC), frequently termed the membrane attack complex when 
inserted into a membrane. The terminal pathway proceeds by the assembly of C7 to 
C5b6 (100). Not dependent on the initial pathway of activation, the C5b-7 complex 
binds C8 and C9 creating a pore that penetrates the membrane leading to 
transmembrane leakage. If there is no membrane present and the activation occurs in 
the fluid phase, C5b-7 binds vitronectin and clusterin which are fluid phase regulators 
of the terminal pathway, leading to formation of the soluble TCC (sC5b-9).   
 
The complement activation products C3a, C4a, C5a are known as anaphylatoxins. 
Human C4a shows proinflammatory properties in guinea pigs by inducing smooth 
muscle contractions, increased vascular permeability and secretion of granules from 
platelets and O2- generation in macrophages (105). No evidence of anaphylactic 
effects is however seen in humans and no receptor for C4a has been described. C4a 
and C3a displayed antibacterial activities against bacterial isolates of Pseudomonas
aeruginosa and Enterococcus faecalis (106). C3a mediates contraction of smooth 
muscles, chemotaxis and activates leucocytes, primarily eosinophils and mast cells 
and mediates increased vascular permeability (105). C5a is the most potent of the 
anaphylatoxins. C5a is a strong chemoattractant not only for neutrophils but also 
monocytes and macrophages, and is involved in the recruitment of inflammatory cells 
(macrophages, neutrophils, activated B- and T-lymphocytes, basophils and mast cells 
as well as the release of granulae-based enzymes and the formation of oxygen radicals 
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(91;107). C5a may also modulate neutrophil and lymphocyte apoptosis, enhance 
expression of adhesion molecules and may activate the coagulation system. C3a and 
C5a mediate several proinflammatory activities when bound to the C3a receptor 
(C3aR) and the C5a receptor (C5aR) respectively. C5a exerts its effects through the 
receptors C5aR and C5L2-receptors. C3a and C5a regulate vasodilatation, increase 
the permeability of small blood vessels and may induce contraction of smooth 
muscles (108).  
 
Complement activation is controlled by fluid-phase and membrane bound inhibitors 
(96). The regulatory mechanisms are balanced so the deposition of complement 
proteins on normal cells and tissues are limited, while complement activation mainly 
takes place on the surfaces of invading pathogens.  
 
Complement deficiencies may lead to severe diseases. Patients with a genetic 
complement deficiency, particularly of the classical pathway have increased 
susceptibility to systemic lupus erythematosus (SLE) and similar diseases (induction 
of tolerance and clearing of immune complexes), but there is also an increased 
activation of the complement system enhancing the inflammatory reaction (100). 
Complement deficiencies increasing the susceptibility to pyogenic infections are 
deficiencies of the opsonic activities of complement leading to increased 
susceptibility to pyogenic organisms, deficiencies that disturb the lytic activity of 
complement leading to increased susceptibility to neisseria infections, and 
deficiencies of the MBL pathway (96). Deficiency of C1-inhibitor (C1-INH) leads to 
a severe condition known as hereditary angioedema (100). Factor H deficiencies leads 
to severe kidney diseases because of uncontrolled activation of C3. Mutations and 
polymorphisms in factor H predispose to membranoproliferative glomerulonephritis 
type II (MPGN II), partial lipodystrophy (PLD), age-related macular degeneration 
(AMD), and atypical familial haemolytic uremic syndrome (aHUS) (109). Mutations 
in the phosphatidyl-inositolglycan classA gene, impairing the synthesis of the 
glycosylphosphatidyl anchor required for insertion of the complement regulatory 
proteins decay accelerating factor (DAF) and CD59, lead to paroxysmal nocturnal 
hemoglobinuri owing to the increased sensitivity of red blood cells to lysis. All 
diseases mentioned above are examples of innate (complement) reactivity against 
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self-tissue under conditions where key complement inhibitors is absent or has an 
abnormal function. 
 
The serum complement system also enhances the adaptive immune response. 
Activation of complement with release of cleavage products that interact with cell 
surface receptors found on several cell types provides a basis for the regulation of B 
and T-cell responses (85). Complement enhances B cell immunity by complement 
receptors CD21 (binds iC3b, C3dg and C3d) and CD35 (binds mainly C3b and C4b). 
Follicular dendritic cells (FDCs) have a high expression of the complement receptors 
CD21 and CD35 which provides an effective mechanism of retention of C3-coated 
immune complexes within the lymphoid compartment. The complement system 
participates also in the regulation of T-cells by several mechanisms like direct 
opsonization of foreign antigens by antigen-presenting cell (APCs) and by modulating 
cytokine release.   
2.9.2 C1-INH
C1-inhibitor is a serine protease inhibitor with a molecular mass of approximately  
105 kDa. The plasma concentration is approximately 0.24 g/L which corresponds to  
1 U/mL (110). C1-INH has a protease inhibitory domain and a long heavily 
glycosylated amino terminal domain (111). It reduces activation of the classical 
complement pathway by binding to C1r and C1s (112) and the lectin complement 
pathway by binding to the MBL-associated proteases, MASP-1 and MASP-2 (113)  
by protease inhibition. C1-INH may also inhibit activation of the alternative 
complement pathway by binding to C3b, preventing the binding of factor B. The latter 
does not depend on covalent binding to the protease (114).  
 
C1-INH treatment has improved the outcome of inflammatory diseases including 
ischemia-reperfusion injury (myocardial, brain, skeletal muscle), hyper acute 
transplant rejection, vascular leak syndromes, as well as Gram negative bacterial 
sepsis and endotoxin shock (115;116). Activation of the complement system plays an 
important role in the pathogenesis of inflammatory diseases while the contact system 
probably is involved in mediation of damage (115). C1-INH’s effects in sepsis and 
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inflammatory disease are not only a result of covalent binding to proteases in the 
complement and contact system, since reactive center-cleaved, inactive C1-INH also 
is beneficial. These effects depend on non-covalent bindings to extracellular matrix 
components, C3b, selectins, Gram negative bacteria, and LPS (115). C1-INH 
concentrate has been administered safely over many years to patients suffering from 
inherited or acquired C1-INH deficiency (111). 
 
2.9.3 Toll-like receptors 
The classical PRRs are the Toll-like receptors (TLRs) which are type 1 
transmembrane proteins with an intracellular signalling cytoplasmic TOLL/IL-1 
receptor (TIR) domain and a leucine-rich repeat extracellular domain (ECD) 
responsible for the binding of a ligand (117). At least 12 different TLRs are described 
in mammals. TLR4 are together with TLR 1, 2, and 6 found on the plasma membrane 
of immune cells and recognize lipoproteins and lipoglycans on the surface of 
microbes. All TLRs except TLR 3 signal through the MyD88 dependent pathway 
leading to the activation of the NFB gene-transcription program and the formation of 
proinflammatory cytokines. While immunostimulatory ligands or PAMPs (LPS, 
peptidoglycan, lipoarabinomanan) are microorganism- specific, host-derived 
immunostimulators like heparan sulphate, hyaluronon, heat-shock proteins, surfactant 
proteins, IFN-, uric acid, fibronectin, -defensin and cardiolipin may signal through 
the same receptors (81).  
 
TLR4-mediated LPS recognition depend on a protein called myeloid differation 
protein 2 (MD-2) which forms a complex with the ectodomain of TLR4 (118). The 
CD14/TLR4/MD-2 complex recognizes lipopolysaccharides from gram-negative 
bacterial cell walls. MD-2 is a soluble protein which facilitates intracellular transport 
of TLR4 and regulates LPS-induced TLR4-clustering (119). MD-2 is a necessary 
cofactor for TLR4 in the detection of LPS and this process is greatly enhanced by 
CD14 and LPS-binding protein (LBP) (120;121),  Soluble MD-2 can bind LPS 
directly with high affinity. This LPS/MD-2 complex forms a ligand that may activate 
TLR4 positive cells (122). MD-2 -/- mice do not respond to LPS (121). They survive 
endotoxin shock but are susceptible to Salmonella typhimurium infection. MD-2 is 
necessary for correct intracellular distribution and LPS-recognition of TLR4. 
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2.9.4 CyP
The cyanobacterial product CyP is a LPS-related molecule derived from the 
cyanobacterium Oscillatoria planktothrix FP1. CyP acts as a specific TLR4/MD-2 
antagonist, binds directly to MD-2 and competitively inhibits the binding of LPS and 
the downstream activation of NFB (123). CyP protects mice from lethal LPS- 
induced shock. Delayed addition of CyP to dendritic cells preincubated with LPS, 
strongly inhibited signalling and cytokine formation by immediate downregulation of 
inflammatory cytokine mRNAs.  Cyp is a potent antagonist of meningococcal LPS 
(124) and an efficient inhibitor of E.coli LPS (125).  
 
2.10 Innate immunity of the newborn 
Physiological demands of the fetal and neonatal immune systems need to protect 
against infection, including virus and bacterial pathogens at the maternal-fetal 
interface (126), avoid potential harmful pro-inflammatory/T helper 1-cell- 
polarization responses that may induce alloimmune reactions between mother and 
fetus , and to mediate the transition between the normally sterile intrauterine 
environment meeting the antigen-rich environment of the outside of the world, 
including primary colonization of the skin (127) and intestinal tract (128) by 
microorganisms. Limited exposure to antigens in utero and well described defects in 
neonatal adaptive immunity (129), results in the fact that newborns must rely on their 
innate immune system for protection to a certain extent. After birth the maturation of 
the immune system is age-dependant (130).  
 
Basal TLR expression in full-term neonatal blood monocytes is similar to that in adult 
monocytes, but despite a higher concentration of monocytes at birth, addition of LPS 
to whole cord blood, resulted in diminished formation of TNF- in cord blood 
compared to in adult blood (131). TLR-mediated formation of IL-6, IL-10 and IL-23 
by neonatal monocytes, macrophages and myeloid DCs was actually enhanced in 
neonatal compared to adult cells (132). There was a high ratio of IL-6 to TNF- 
production by mononuclear cells. According to Levy, neonatal monocytes express 
normal basal levels of membrane CD14 and TLR4, but the levels of CD14 may be 
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low in prematures (133). After stimulation with LPS, neonatal neutrophils and 
monocytes demonstrate reduced expression of CD14 compared with adult cells. LPS-
induced CXCL8 release were higher in neonatal peripheral blood leukocytes 
compared to adult (134). When pretreated with anti-TLR4 and anti-CD14, CD14 
blockade induced an approximately 3-fold greater inhibition of CXCL8 compared 
with anti-TLR4. Neonates depended more on TLR4 for CXCL8 release. 
 
Cord blood is known to contain approximately half the amount of complement 
components compared to adult blood (135;136). 
2.11 Previous studies performed on meconium at the Institute of 
Immunology and the Department of Pediatric Research 
Several studies have been performed at the Department of Pediatric Research and the 
Institute of Immunology concerning meconium and MAS. In an experimental model 
of MAS in newborn pigs Tølløfsrud et al hypothesized that lipids and bile acids in 
meconium were components responsible for meconium-induced lung injury (137). 
Albumin may bind these components. Albumin mixed with meconium before 
instillation, significantly reduced the detrimental effects of meconium in newborn pigs 
measured by oxygenation index (OI), ventilation index (VI) and dynamic compliance. 
If we look further into this paper, maximum oxygenation index was very low in both 
groups, 6.1 in the meconium group versus 3.1 in the meconium/albumin group. Both 
these values are so low that if not anaesthetized, neither group of pigs would probably 
need to be put on the respirator.  Instillation of albumin as a rescue in the same model 
of MAS in newborn pigs, improved lung compliance (138).  
 
Castellheim et al found meconium to be a potent activator of the complement system 
in vitro (49). Meconium activated the complement system also in vivo reflected by 
increased TCC in an experimental model of MAS in newborn pigs (50). Complement 
activation measured by TCC was followed by increased formation of 
proinflammatory cytokines as an indication of a systemic inflammatory response. The 
increased TCC was correlated with deteriorated lung function and increased mortality.  
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3 AIMS OF THE STUDY 
Meconium aspiration syndrome is a severe disease with a complex and not well 
defined pathophysiology. Despite ongoing research for interventional strategies, 
treatment of this disease is still only supportive.  
 
In paper I, a continuum of earlier research performed at the Department of Pediatric 
Research, we used an in vivo model of MAS. We investigated if albumin-lavage 
would be an effective therapy. This treatment actually made the pigs worse. The 
animal model was far from optimal, since this disease has a complex, not well defined 
pathophysiology. We therefore found it necessary to learn more about the 
pathophysiology of MAS before trying to treat the disease. Our main aim became to 
investigate the pathophysiology of MAS with emphasize on activation of the innate 
immune system further.  
 
Finally, if for instance complement inhibition or a combined inhibition of the 
CD14/TLR4/MD-2 complex would be an approach to decrease the inflammatory 
reaction in MAS, it would be interesting to know the immunity status of our research 
animals and also to follow the effect of our treatment, thereby paper V.  
 
 
Paper I 
The first study was a continuum of earlier studies performed at the Department of 
Pediatric Research investigating the hypothesis of albumin as a neutralizer of toxic 
substances in meconium. The aim of this study was to explore whether instillation of 
albumin as a rescue after meconium and cleansing the airways by lavage would 
improve lung function and reduce the inflammatory response.   
 
Paper II 
Earlier studies have shown that meconium activates the complement system via the 
alternative pathway (49). New methods and reagents were now available. The aim of 
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the first part of this study was to investigate the initial mechanisms of meconium-
induced complement activation.  
 
C1-inhibitor (C1-INH) is a known inhibitor of classical and lectin pathway activation 
and may also reduce alternative pathway activation. C1-INH treatment has improved 
the outcome of several inflammatory diseases. In the second part of this study we 
therefore wanted to investigate to what extent C1-INH concentrate modified the 
meconium-induced inflammatory reaction in cord whole blood.  
 
Paper III 
The complement system and the CD14/TLR4/MD-2 complex are two main branches 
of innate immunity. The aim of this study was to investigate whether meconium, in 
addition to activing complement, also could induce CD14-mediated cytokine 
production and to what extent LPS was involved. We also compared the inflammatory 
effects of meconium in adult and cord whole blood. 
 
Paper IV 
Meconium activates complement and CD14 and may induce a systemic inflammatory 
response. Toll-like receptors are classical pattern-recognition receptors recognizing 
both exogenous and host derived ligands. The cyanobacterial product CyP is a potent 
LPS antagonist binding to the TLR4/MD-2 complex. The aim of this study was to 
investigate the role of the TLR4/MD-2 complex in meconium-induced inflammation 
by comparing the effect of MD-2 inhibition by CyP with CD14- inhibition in human 
whole blood and to investigate the involvement of CD14, MD-2, TLR4 and TLR2 in 
human transfected cell lines.    
 
Paper V 
Antibodies and tests used to evaluate medical research are not always applicable in 
animals. The human Wielisa test measures complement activity in human serum. The 
immunity status of our research animals may be useful in for instance sepsis research. 
The aim this study was to evaluate the applicability of the human Wielisa-test in pigs 
by investigating pig complement activity as well as monitoring the effect of 
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complement inhibition, both in in vitro and in vivo models. We also aimed to use the 
test to see if pigs expressed variable lectin pathway activity, consistent with a certain 
percentage of MBL-deficiency. 
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4 METHODS
4.1 Informed consent and approval 
Informed consent was obtained from all donors and parents of healthy newborns 
donating cord blood. The studies were approved by the Norwegian Regional Ethical 
Committee. The experimental animal model was approved by the National Animal 
Research Authority (NARA) and the pigs were handled and cared for in accordance to 
guidelines.  
4.2 Meconium
Meconium was collected with a wooden-spatula from diapers of 48 healthy newborns 
and stored in 50 mL propylene centrifuge tubes (Corning Inc., Acton, MA) at -20C. 
The meconium was then thawed, pooled and processed in PBS and then freeze dried 
(HETO-FD3; Heto, Holten, Denmark). The meconium was reconstituted with PBS to 
a final concentration 100 mg/mL and then frozen in aliquots at -20C until the day of 
the experiment. No bacteria were detected after cultivation. The LPS content of the 
meconium used in paper I-IV was measured using a standard Limulus Ameboecyte 
Lysate Assay (LAL QCL-1000, Cambrex Bio Science, Walkersville, MD), and found 
to be 20 pg/mg meconium. The endotoxin or LPS content in meconium used in paper 
V, was analyzed in a Pyrochrome® Limulus Amoebocyte Lysate assay by an endpoint 
chromogenic method using a diazo-coupling assay kit. The LPS content in the 
meconium was found to be 30 EU/mg meconium or 3 ng LPS per mg meconium.
 
4.3 In vitro 
4.3.1 The whole blood model 
The in vitro whole blood model using the highly specific thrombin inhibitor lepirudin 
(recombinant hirudin analog, Refludan®) as an anticoagulant (139) has been 
developed in our laboratory. Lepirudin does not alter complement activation in 
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contrast to other anticoagulants like EDTA, citrate and heparin. Lepirudin 50 μg/mL 
whole blood was used in all whole blood experiments. 
4.3.2 Reagents
All materials and solutions in this study were endotoxin-free according to the 
manufacturers. Polypropylene tubes were NUNC cryotubes (Nalgene NUNC, 
Roskilde, Denmark).  Sterile phosphate-buffered saline (PBS) was from Dulbecco 
(Paisley, United Kingdom), lepirudin (Refludan®) from Hoechst (Frankfurt am Main, 
Germany), heparin from Løwens Kemiske Fabrik (Ballerup, Denmark), C1-INH 
concentrate (Cetor®) from Sanquin CLB (Amsterdam, The Netherlands), human 
serum albumin and immunoglobulin G (IgG) (Octagam®) from Octapharma AG 
(Lachen, Switzerland). CyP was purified from the freshwater cyanobacterium 
Oscillatoria planktothrix FP1 by a phenol-guanidium thiocyanate-based method as 
described previously (123) and was a gift from Carlo Rossetti. 
4.3.3 Antibodies
Mouse monoclonal antibodies blocking C2 (clone 175-26, IgG1) and factor D (clone 
166-32, IgG1) and an isotype-matched control (clone G3-519, IgG1) were produced 
and purified under identical conditions (140;141). The combination of anti-C2 and 
anti-factor D efficiently block all three initial pathways of complement. Mouse anti-
human CD14 (clone18D11; purified IgG1 and F(ab’)2) was purchased from Diatec 
(Oslo, Norway). Mouse anti-MBL monoclonal antibodies (mAbs) binding to different 
epitopes on MBL, were a gift from G.L.Stahl, Harvard Medical School. 3F8 (IgG1) 
inhibits MBL-dependent C3 deposition on mannan-coated plates (142) while 1C10 
(IgG2b) is non-inhibiting (143). 
 
4.3.4 ELISA
Several different enzyme-linked immunosorbent assays (ELISAs) exist (144;145).  In 
the double antibody sandwich ELISA, an antibody is attached to the bottom of a well 
and provides antigen capture and specificity. Another antibody linked to an enzyme 
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provides detection and an amplification factor. The wells are coated with a capture 
antibody; the plate is incubated with for instance serum or plasma containing the 
inflammatory mediator we want to measure. The detection antibody which is linked to 
an enzyme is added before adding the substrate and a color change appears. 
 
In paper I, TNF, IL-1, IL-6, and IL-8 were analyzed using commercial available 
enzyme immunoassays, performed according to instructions provided by the 
manufacturer (R&D Systems, Oxford, UK). 
4.3.4.1 TCC
Complement activation was measured by quantification of the terminal sC5b-9 
complex (TCC) using an enzyme-linked immunosorbent assay (ELISA) as previously 
described and later modified (146;147). The assay is based on a monoclonal antibody 
(aE11) highly specific for a neoepitope exposed in C9 when incorporated into TCC. 
Values are given in arbitrary units (AU) defined by a serum standard activated with 
zymosan and defined to contain 1000 AU/mL. 
4.3.4.2 C1rs/C1-INH complexes, C4d, C3bBbP 
Enzyme immunoassays (EIAs) based on mAbs recognizing products of the different 
pathways, were used to measure complement activation. C1rs/C1-INH complexes 
reflecting CP activation, was quantified as previously described (148). C4d, reflecting 
CP and LP activation was measured using the Quidel C4d Fragment Enzyme 
Immunoassay (Quidel, San Diego, CA). C3bBbP, the properdin-containing AP 
convertase reflecting AP activation, was quantified as previously described (139). 
Values for all activation products except C4d are given in arbitrary units (AU) defined 
by serum standards activated with heat aggregated IgG and zymosan and defined to 
contain 1000 AU/mL. C4d are given in μg/mL according to a standard delivered by 
the kit. 
 36
4.3.4.3 Wielisa
Platelets are coated with IgM for measurement of CP activation, mannan for 
measurement of LP activation, and lipopolysaccharide from Salmonella typhi for 
measurement of AP activation (149;150). Serum is diluted in specific buffers 
according to the activating pathway. For CP activation, human serum is diluted 1:101 
in a veronal buffer containing both free calcium and magnesium. For LP-activation, 
human serum is diluted 1:101 in a veronal buffer containing free calcium and 
magnesium and monoclonal anti-C1q antibodies to prevent CP activation. For AP 
activation, human serum is diluted 1:18 in a Mg-EGTA buffer with free magnesium 
and no calcium. Serum is then incubated for one hour at 37C. After washing, alkaline 
phosphatease-conjugated antihuman C5b-9 (clone aE11) is added before a new 
incubation for 30 minutes. The monoclonal antibody aE11 reacts with a neoepitope 
exposed in C9 after incorporation in the C5b-9 complex. aE11 cross-reacts with 
specific pig epitopes (151). 
 
4.3.5 Multiplex
Multiplex arrays are developed from traditional ELISAs to measure multiple 
mediators at the same time (145). They are based on the utilization of flowcytometry, 
chemiluminiscence or electrochemiluminiscence technology. The Luminex 
multianalyte profiling technology employ proprietary bead sets which are 
distinguishable under flowcytometry. Each bead set is coated with a specific capture 
antibody and fluorescence or streptavidin-labeled antibodies bind to the specific 
cytokine capture antibody complex on the bead set. The following cytokines, 
chemokines and growth factors were measured on a Bioplex Array Reader 
(LUMINEX 100, Bio-Rad Laboratories, Hercules, CA) using Bio-Plex Human 
Cytokine 27-plex panel (Bio-Rad Laboratories, Hercules, CA): IL-1Ra, IL-1, IL-2, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, TNF-, IFN-
, MIP-1, MIP-1, eotaxin, MCP-1, G-CSF, GM-CSF, basic FGF, VEGF, IP-10, 
RANTES, and PDGFbb. 
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4.4 In vivo 
4.4.1 The animal model 
The anatomy and physiology of newborn pigs as well as body weight are comparable 
to human newborns (152). Pigs are not genetically identical as rodents. Newborn 
Noroc (LYxLD) pigs (crossbred between Norwegian Landrace (L) ½, Yorkshire (Y) 
¼ and Duroc (D) ¼), 12-36 hours old, were delivered by a local farmer on the day of 
the experiment. 
4.4.1.1 Animal Preparation, Anaesthesia and Surgery 
Most anaesthetics have cardiodepressive effects. All animals received the same drugs 
indicating that these effects would influence the control group as well as the 
interventional group. 
 
In paper I, anaesthesia was induced by halothane 4 % in an equal mixture of air and 
oxygen (3L + 3L) until sleep, maintenance level of halothane was 1-2%. In paper IV, 
anaesthesia was induced by sevofluran 7 %, reduced to a maintenance level of 2 %. 
An ear vein was cannulated. The pigs were tracheotomised using local infiltration 
anaesthesia (lidocain 10mg/mL, maximum7 mg/kg) and ventilated through an 
uncuffed endotracheal tube, inner diameter 3.5 mm (Portex Ltd., Hythe, Kent, UK) by 
a Babylog 8000 plus ventilator (Dräger Medical AG, Lübeck, Germany), shortly 
interrupted by manual ventilation (Laerdal silicon resuscitation bag, infant size; 
Laerdal, Stavanger, Norway). After tracheotomy intravenous anaesthesia replaced 
halothane/sevoflurane by boluses of pentobarbital sodium (20 mg/kg) and fentanyl 
(12-20 g/kg) and maintained by infusion of fentanyl 25-50 g/kg/h and midazolam 
250 g/kg/h. A continuous intravenous infusion containing 0.7 % NaCl and 1.25 % 
glucose at 6 mL/kg/h was given through polythene catheters (Portex PE-50, ID 
0,96mm, Portex Ltd., Hythe, Kent UK) by syringe pumps (IVAC P 2000, 
Basingstoke, UK, and THERUMO STC-521, Tokyo, Japan). 
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Halothane depresses cardiovascular function, but these effects are time and dose 
dependant. Halothane may cause malignant hyperthermia and tetanus in older pigs 
(153). Sevoflurane induces anaesthesia faster than halothane. It may also have cardio-
depressive effects, but it is used in pigs and other animals both in research and in 
veterinary medicin (154;155). The barbiturate Pentobarbital was used for induction 
and the final overdose. Pentobarbital have cardio-depressive effects which are dose-
dependent, but are generally well tolerated in pigs (156). 
 
Fentanyl and midazolam were used for analgesia and sedation. Pigs may need 
relatively large doses of opioids for analgesia (157;158). Midazolam is an effective 
sedative in pigs with minimal cardiovascular effects (159).  
 
Volume resuscitation with 10-20 mL NaCl 9 mg/mL up to three times during the 
experiment was given if needed.  Central venous access was via the external jugular 
vein. Mean arterial blood pressure was recorded by a polythene catheter placed in the 
femoral artery. By means of pressure transducers (Edwards Life Science, Hina, 
Dominican Republic), hemodynamic data were collected in a computer system 
(Model MP 100, Biopac systems Inc., Santa Barbara, CA). Initial ventilator setting 
was peak inspiratory pressure (PIP) 18-20 cm H2O, ventilator rate 30/min, positive 
end expiratory pressure PEEP) 4 cm H2O, inspiratory time 0.4 s, and  fraction of 
inspired oxygen (FiO2) 0.21. During the experiment, PIP could if needed be increased 
to maximum 45 cm H2O and the ventilator rate until maximum 60/min to keep tidal 
volume at 8-14mL/kg, arterial oxygen saturation at 	 90 % and PaCO2 at 4-7 kPa. 
End-tidal CO2 was continuously monitored (Datex Normocap Oxy, Datex, Helsinki, 
Finland). Rectal temperature was kept between 38.5 and 39.5 C with a heating lamp 
or a heating blanket. At the end of the experiment the pigs were killed with a bolus- 
injection of pentobarbital sodium.       
                                                                                                                   
4.5 Data presentation and Statistics 
Paper I 
Data are given as medians with interquartile ranges. Nonparametric tests were used 
for statistical analysis. Wilcoxon signed rank test was used for in-group differences, 
Mann-Whitney Wilcoxon test when comparing two groups, and Kruskal-Wallis test 
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when comparing three groups. A two-tailed p-value below 0.05 was considered 
significant. 
Paper II 
Groups in figure 1 were compared using Mann-Whitney U Test in PRISM (Graph Pad 
Software Inc, San Diego, CA). The data are presented as medians with interquartile  
ranges. A two-tailed p-value below 0.05 was considered significant.
Groups in figures 2-5 were compared in a two-way repeated measurements analysis of 
variance (ANOVA) in PRISM (Graph Pad Software Inc, San Diego, CA) to explore 
the effect of dose and treatment. The data are presented as mean values with 95 % 
confidence intervals. A two-tailed p-value below 0.05 was considered significant. 
Paper III 
Data are given as medians and interquartile ranges of 6 different experiments for all 
parameters except for IL-8 and LPS, where data are give in medians and ranges of 
three experiments. Due to the large numbers of readouts and experiments with 
different inhibitors and their combinations, statistical calculation was limited to the 
primary study aim, namely to compare the meconium-induced increase of a mediator 
with the effect of the combined inhibition with complement and anti-CD14. 
Nonparametric Wilcoxon’s test was used for experiments with 6 observations and 
Student-t test with three. A two-tailed p-value below 0.05 was considered significant.  
Paper IV 
Data from the titration of CyP and meconium (n=2) are presented as means with 
ranges. Data from the inhibition with CyP and anti-CD14 are presented as means with 
95% confidence interval. Data from the inhibition experiment are compared using 
repeated measurements ANOVA with Tukey as a post test. A two-tailed p value 
below 0.05 was considered significant. 
Paper V 
Data are presented as medians of absorbance values (Figure 1) and standardized to 
values using NHS diluted 1/101 (set at 100%) with range in Figure 2, 3 and 5 and in a 
frequency distribution histogram for Figure 4. 
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5 MAIN RESULTS  
 
Paper I 
Albumin lavage does not improve the outcome of meconium 
aspiration syndrome 
In this study of experimental meconium aspiration syndrome in newborn pigs we 
found that albumin lavage did not improve the outcome, rather the opposite. OI, VI, 
FiO2, and TCC increased significantly and compliance decreased significantly in the 
meconium-albumin group compared to the meconium group. There were no 
significant differences in release of proinflammatory cytokines between the two 
groups.  
 
Paper II 
Mechanisms of complement activation and the effects of C1-inhibitor 
on the meconium-induced inflammatory reaction in cord blood 
This study demonstrated for the first time a role for the lectin pathway in meconium-
induced complement activation. Meconium activated the lectin complement pathway 
as well as the alternative complement pathway. 
 
We also found a substantial inhibitory effect of C1-INH in supraphysiological 
concentrations in cord blood, attenuating the meconium-induced release of a broad 
panel of cytokines, chemokines and growth factors. In fact, all mediators induced by 
meconium measured in this study were inhibited considerably by C1-INH.  
 
Paper III 
Role of complement and CD14 in meconium-induced cytokine 
formation
In this study we demonstrated for the first time that meconium induced a potent 
CD14-mediated inflammatory reaction reflected by synthesis of a broad panel of 
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cytokines, chemokines and growth factors in adult and cord human whole blood.  
Inhibition of CD14 markedly reduced the production of a number of the inflammatory 
mediators; complement inhibition reduced some of the mediators to a certain extent, 
whereas the combined inhibition of CD14 and complement had a remarkable effect on 
virtually all of the mediators studied. This combined effect was more pronounced than 
could be predicted from the effect of separate inhibition of CD14 and complement. 
Thus, these data indicate a synergistic effect of blocking these two main branches of 
innate immunity on the inflammatory response induced by meconium. The 
meconium-induced cytokine formation was generally more potent in cord blood than 
in adult blood. In general, cord blood seemed to be more sensitive to meconium-
induced activation than adult blood and the effect of inhibition of CD14 and 
complement was also more efficient in cord blood. 
 
The LPS content of meconium used in this study was low. Adding LPS in increasing 
concentration to meconium did not increase the meconium-induced cytokine 
formation further, indicating that the CD14-mediated inflammatory response must be 
caused by other factors than LPS, probably endogenous substances. 
 
Paper IV 
Meconium-induced release of cytokines is mediated by the TLR4-
MD2 complex in a CD14-dependant manner 
 
In this study we demonstrated that meconium-induced cytokine, chemokine and 
growth factor formation mainly is mediated through the TLR4/MD-2 complex as 
shown by a substantial inhibition of biomarker release using the LPS antagonist CyP. 
We further demonstrated the necessity of CD14 in meconium-induced activation of 
the TLR4/MD-2 complex. Experiments using cells transfected with TLR2/TLR4, 
MD-2, and/or CD14, using TLR9 as control, confirmed these data. Thus the 
previously observed dependency of meconium-induced cytokine formation can be 
attributed to signalling via the CD14/TLR4/MD-2 complex. Finally the TLR4/MD-2 
complex seemed to be involved in meconium-induced inflammation by endogenous 
mechanisms. 
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Paper V 
Pathway-specific complement activity in pigs evaluated with a human 
functional complement assay 
This paper demonstrated for the first time that normal pig serum has a fully active CP, 
LP, and AP detected in a human assay for total complement activity. LP activity was 
consistent with a distribution of MBL-deficiencies similar to that found in humans. 
Finally, the assay can be used to evaluate and monitor complement inhibition both in
vitro and in vivo. 
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6 DISCUSSION
6.1 Etiological consideration 
Despite a declining incidence of severe MAS in the developed world, MAS is still a 
major cause of respiratory distress in term and post term infants especially in the 
developing world (5;160). Extensive research on prevention and intervention has been 
performed. Still only supportive treatment is generally used and the only intervention 
that probably has declined the incidence is delivery at term. The pathophysiology is 
still poorly understood, especially the prenatal events leading to meconium aspiration 
and the fact that some children may aspirate meconium without the development of 
severe symptoms or complications.  
 
6.2 Albumin and the animal model 
In our first paper we used an experimental model of meconium aspiration syndrome in 
newborn pigs. Several animal and also a few human studies using surfactant in MAS 
have been performed. Repeated bolus doses of surfactant probably reduced the need 
for ECMO in ventilated children suffering from MAS (65;66). Therapeutic lung 
lavage using surfactant has been performed in several animal models, but few 
randomized controlled studies are published. A Cochrane review concludes that 
surfactant administration may reduce the severity of respiratory illness and decrease 
the number of infants with progressive respiratory failure requiring ECMO (69). 
Tølløfsrud compared the instillation of meconium alone with meconium mixed with 
albumin in newborn pigs and found significantly reduced oxygenation index, 
ventilation index and increased dynamic compliance (137). We instilled albumin 5 
min after instillation of meconium to lavage the lungs. Albumin was meant to bind 
and neutralize detrimental components of meconium, and the lavage should help clean 
the airways. Albumin lavage had no effect on MAS, rather the opposite (paper I). We 
also found that this animal model was far from optimal. Some of the pigs got very 
sick while others did very well. The fact that prenatal events contribute considerably 
to severe MAS (12;161) makes it difficult to find an optimal animal model. 
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6.3 Complement activation 
In paper II we confirmed earlier findings that meconium is a potent activator of the 
complement system (49) through the alternative complement pathway. As the 
alternative pathway acts as an amplification loop of all initial pathways (101;104) we 
studied a possible role for the lectin pathway as an initial activation mechanism in 
meconium-induced complement activation. The fact that the inhibitory anti-MBL 
antibody 3F8, reduced meconium-induced C4d formation suggests that meconium 
activates the lectin pathway directly (paper II). Meconium-induced formation of TCC 
was less reduced than C4d, indicating that the alternative pathway seems to be 
activated directly by meconium as well as being amplified after the initial lectin 
pathway activation. This is in accordance with recent view that the alternative 
pathway both act as an initial recognition system via properdin, as well as amplifying 
the other initial pathways (97). 
 
6.4 C1-inhibitor
In paper II we investigated the effect of the serine protease C1-INH on meconium-
induced inflammation in cord whole blood. We demonstrated for the first time a 
substantial inhibitory effect of C1-INH, reducing meconium-induced formation of 
cytokines, chemokines and growth factors by an average of 60-70%. C1-INH controls 
the classical pathway proteases C1r and C1s (112), and also regulates lectin pathway 
by inhibiting its main protease MASP-2 (113). This may explain why C1-INH 
reduced C4d formation in our study. The inhibitory effect of C1-INH on the 
alternative pathway activation product, C3bBbP, can be explained both by a combined 
effect of less activation of the lectin pathway and thereby less triggering of the 
amplification loop, and also by a protease independent interaction between C1-INH 
and C3b, preventing the binding of factor B (114).  
 
MAS is associated with an inflammatory response (50;53;53) and the fact that C1-
INH in supraphysiological conditions substantially inhibited meconium-induced 
formation of all inflammatory mediators induced by meconium, makes it interesting 
to consider C1-INH infusion to be an alternative approach to reduce the inflammatory 
response in MAS. 
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6.5 Complement, TLRs and LPS 
The complement system and the CD14/TLR4/MD-2 complex are two main branches 
of innate immunity. In paper III we demonstrated that the meconium- induced 
inflammatory response is mediated through the main branches of the innate immune 
system, the CD14/TLR4/MD-2 complex and complement in human whole blood and 
cord blood. We demonstrated for the first time that meconium induced a potent 
CD14-mediated inflammatory reaction reflected by synthesis of a broad panel of 
cytokines, chemokines and growth factors in both human adult and cord whole blood. 
Inhibition of CD14 markedly reduced the formation of many mediators, inhibition of 
complement reduced some of the mediators, but the combined effect of inhibiting 
both systems had a remarkable effect on almost all mediators induced by meconium. 
The combined effect was more pronounced than could be predicted by separate 
inhibition alone, indicating a synergistic effect. This effect has not been described for 
meconium earlier. Brekke et al. found that the combined inhibition of both 
complement and CD14 in human whole blood blocked E.coli-induced granulocyte 
and monocyte up-regulation of CD11b, abolished oxidative burst and reduced 
phagocytosis (162). The combined inhibition also inhibited E.coli-induced 
inflammatory respone in human whole blood measured by several inflammatory 
mediators (163) as shown in our study.  
 
The role of the TLR4/MD-2 complex was further investigated in paper IV, comparing 
the effect of MD-2 inhibition by CyP with CD14 inhibition, and the investigation of 
CD14, MD-2 and TLR4 in human transfected cell lines. We demonstrated for the first 
time that meconium-induced cytokine, chemokine and growth factor formation 
mainly is mediated through the TLR4/MD-2 complex as shown by a substantial 
inhibition of biomarker-release using the LPS-antagonist CyP. Furthermore, we 
documented the requirement of CD14 for this response using transfected cells. The 
specificity of TLR4 was also shown in the transfected cells by including TLR2 and 
TLR9 transfectants. Thus, the previously observed CD14-dependency of meconium-
induced cytokine formation in paper III can be attributed to signaling via the 
CD14/TLR4/MD-2 complex. 
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MD-2 is a necessary cofactor for TLR4 in the detection of LPS. This process is 
greatly enhanced by CD14 and LPS-binding protein (120;121)  Soluble MD-2 binds 
LPS directly with high affinity and the LPS/MD-2 complex forms a ligand activating 
TLR4-positive cells (122). CyP binds the TLR4/MD-2 complex directly, 
competitively inhibiting binding to LPS (123). CyP protects mice from LPS-induced 
shock and exerts its inhibitory activity in dendritic cells by immediately 
downregulation of inflammatory cytokine mRNAs even if added hours after LPS.  
CyP is a potent antagonist of meningococcal LPS (124) and an efficient inhibitor of E.
coli-LPS-induced cytokine release (125). In the present study CyP decreased 
meconium-induced formation of most mediators measured considerably and to 
virtually the same extent as anti-CD14, suggesting that the CD14-dependent effect of 
meconium-induced inflammation is mediated solely through the TLR4/MD-2 
complex.  
 
6.6 LPS and endogenous activation of the inflammatory response 
Meconium and amniotic fluid have been considered to be sterile as well as the 
gastrointestinal tract of the normal fetus (29). However, several bacteria have been 
detected in meconium samples from healthy newborns (31), the prevalence of positive 
amniotic fluid cultures was significantly higher in women with MSAF and intact 
membranes than in women with clear fluid (20), and fetal membranes, even from 
deliveries by cesarean section at term, have microbial organisms present (30). 
Meconium may contain various amounts of proinflammatory substances including 
TNF-, IL-1, IL-6 and IL-8 (28). In vitro meconium is chemotactic to neutrophils 
(33) and possibly vasoactive (34). Toxic effects of meconium trigger inflammation in 
the lungs (39;47). Activated neutrophils and macrophages are detected in the lung 
parenchyma and alveoli only hours after meconium aspiration (48). The release of 
proinflammatory cytokines may directly injure the lung parenchyma resulting in 
vascular leakage causing pneumonitis and pulmonary edema (51;52). Meconium-
induced inflammatory lung injury is associated with respiratory epithelial apoptosis in 
several animal models (52;54).  
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The cellular response of innate immunity is composed mainly of the TLR family with 
the CD14/TLR4/MD-2 complex as a main constituent. LPS is the main exogenous 
ligand for TLR4, but there are a number of endogenous candidates (e.g. heparan 
sulfate, hyaluronon, fibrinogen) (164). The LPS content in meconium used in paper 
III was as low as 20 pg/mg meconium. LPS contents in the range of μg/mL is needed 
to induce complement activation (162;165). Thus, the complement activation potency 
of meconium is not related to LPS, although a potential for LPS to induce cytokine 
production can not be fully excluded. If there should be a contribution from LPS in 
the meconium-induced cytokine formation, C1-INH is in fact a candidate for 
neutralizing this effect in a complement-independent manner. Zhang et al 
demonstrated that a peptide from the amino-terminal end of C1-INH neutralizes LPS 
either by direct binding to LPS or competing with its receptor on CD14 (166). 
Contamination of meconium by bacterial products including LPS should be carefully 
considered. In paper V, the LPS content of the meconium was 30 EU/mg meconium 
(or 3 ng/mg meconium). In paper III we investigated the role of LPS in meconium-
induced cytokine formation by comparing meconium-induced and LPS-induced 
cytokine formation in human blood. The cytokine formation induced by meconium 
containing 20 pg LPS/mg, at 1 mg meconium/mL whole blood, was considerably 
higher than that induced by LPS at concentration up to 10 ng/mL blood. In paper IV 
we found a higher LPS content of meconium than in the paper III, most likely 
reflecting the different LPS-assays used. We therefore again compared LPS and 
meconium-induced proinflammatory cytokine formation in “LPS-equivalent” doses 
and found a dose-dependent increased formation of TNF, IL-1, IL-6 and IL-8 with 
increasing concentrations of meconium and LPS. Meconium-induced cytokine 
formation was 5-15 folds higher compared to the increase seen with equivalent doses 
of LPS. The relative difference increased with increasing concentrations of 
meconium. We therefore conclude that LPS, although contributing to a certain extent, 
could not explain the meconium-induced inflammatory reaction. Meconium contains 
innumerable agents which are candidates for endogenous danger signaling, in 
particular since it contains “damaged self”. Cell-surface TLRs are known to respond 
to many endogenous ligands like heparan sulfate, hyaluronan, fibrinogen, surfactant 
protein A, fibronectin, HMGB1 and -defensin (164;167).  We therefore suggest that 
the inflammatory response induced by meconium, mainly is mediated by endogenous 
ligands, although the candidate substances are currently unknown. It was out of scope 
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of the present study to search for candidate substances, but it will be important to 
continue this research in order to identify actual ligands.    
 
6.7 Cord blood versus adult blood 
As MAS is a disease of the newborn, the study in paper II was performed in cord 
blood. The study in paper III was performed in both adult and cord human whole 
blood, the latter to emphasize the relevance of the disease and the former to pinpoint 
the difference between immature and mature immunity. We found that meconium-
induced cytokine formation was generally more potent in cord blood than in adult 
blood. The effect of inhibition of meconium-induced cytokine formation by inhibiting 
either complement or CD14 was more efficient in cord blood compared to adult 
blood, but the combined inhibition of both systems almost completely abolished the 
formation of proinflammatory cytokines and chemokines in both adult and cord 
blood. In contrast, in a study performed by Bessler et al, using cells isolated from cord 
blood, there were fewer CD14-positive mononuclear cells and a lower CD14 content 
on each cell compared to adult blood (168). According to Levy, neonatal monocytes 
express normal basal levels of membrane CD14 and TLR4, but levels of CD14 may 
be low in prematures (133;134). After stimulation with LPS, neonatal neutrophils and 
monocytes demonstrate reduced expression of CD14 than adult cells. 
 
Cord blood is known to contain approximately half the amount of complement 
components compared to adult blood (135;136). That is in accordance with our 
finding in newborn pigs in paper IV.  
  
6.8 Testing of porcine complement activity 
In for instance sepsis research, large animals as pigs are commonly used as research 
animals. They are seldom genetically identical as rodents, so their immunity status 
may differ. In paper V, we demonstrated for the first time that normal pig serum has a 
fully active CP, LP, and AP detected in a human assay for measurement of total 
complement activity. LP activity was consistent with a distribution of MBL-
deficiencies similar to that found in humans consistent with previous findings (169).  
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Newborn pigs showed lower activity in all three complement activation pathways 
compared to older animals. The human Wielisa test may also be used in pigs after 
certain modifications (Paper V). Inhibition of pig complement in vitro and monitoring 
inhibition in vivo can successfully be studied. Thus, we assume that the human 
Wielisa test will be a useful tool for investigating complement activity in 
experimental pig models. Finally, the assay can be used to evaluate and monitor 
complement inhibition both in vitro and in vivo. 
 
6.9 Limitations
The main limitation to our findings in paper II-IV is that these studies are in vitro 
studies. The incubation period was four hours. This is the period in which the 
physiological conditions in the blood are relatively stable. Other cell types are also 
present in the lung and participate in lung injury in vivo so our results should be 
interpreted with caution. However, most proinflammatory cytokines and chemokines 
induced by meconium in our studies were significantly elevated in sera from neonates 
with MAS as well as the anti-inflammatory cytokine IL-10 (53). The effect of 
complement inhibition, anti CD14 and CyP may be different in vivo. 
 
6.10 Clinical application 
Prenatal events are important. The pathophysiology of MAS needs further 
investigations, including the prenatal events. Some of our findings like the synergistic 
effect of inhibiting both complement and the CD14/TLR4/MD-2 complex and the 
ability of C1-INH concentrate to reduce the meconium-induced inflammatory 
response, may be potential mechanisms we can explore further with the intention to 
reduce the inflammatory reaction in MAS.  
 
6.11 Future perspectives   
Further investigations considering the pathophysiology of MAS are important 
especially the prenatal events, but also inflammatory aspects. Our present and future 
findings with the intention to reduce the inflammatory response of MAS need to be 
tested in vivo. Appropriate animal models must be thoroughly chosen. 
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Meconium is an interesting substance in studies of inflammation. Especially the 
activation of TLR4 by endogenous mechanisms and probably also to an extent by 
exogenous mechanisms that are not described earlier.  Investigating these mechanisms 
further would be important in order to develop a rational for causal treatment of the 
inflammatory aspects of MAS. 
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7 CONCLUSIONS 
1: Albumin lavage did not improve the outcome of experimental meconium aspiration 
syndrome in newborn pigs, rather the opposite as OI, VI, FiO2, significantly increased 
and dynamic compliance significantly decreased in the meconium-albumin group. 
2: Meconium activated the lectin complement pathway as well as the alternative 
complement pathway. C1-INH in supraphysiological concentrations substantially 
inhibited meconium-induced inflammation in human whole blood.  
3: Meconium induced a potent CD14-mediated inflammatory reaction reflected by 
synthesis of a broad panel of cytokines, chemokines, and growth factors in human 
adult and cord whole blood. The combined inhibition of both complement and CD14 
showed a remarkable effect of almost all mediators induced by meconium, suggesting 
a synergistic effect of blocking these two main branches of innate immunity. The 
CD14 effect cannot be explained by the lipopolysaccharide content of meconium.  
4: Meconium-induced cytokine, chemokine and growth factor formation is mediated 
through the TLR4/MD-2 complex as shown by a substantial inhibition of the 
biomarker release by using the LPS antagonist CyP. CD14 is required for this 
response. Meconium contains substances that may activate the TLR4/MD-2 complex 
mainly by endogenous mechanisms. 
5: Normal pig serum has a fully active CP, LP, and AP detected in a human assay for 
total complement activity. LP activity was consistent with a distribution of MBL-
deficiencies similar to that found in humans. The assay may also be used to evaluate 
and monitor complement inhibition both in vitro and in vivo.  
 
In general: 
Meconium-induced inflammation is mediated by complement and the 
CD14/TLR4/MD-2 complex. Pathophysiological mechanisms need further 
investigations, though our results using a combined inhibition of both these main 
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branches of innate immunity must be an interesting approach to treat the 
inflammatory reaction in MAS. 
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ABSTRACT
OBJECTIVE 
Meconium, the first intestinal discharge of the newborn, contains material 
accumulated during fetal life. Meconium activates complement and CD14 and may 
induce a systemic inflammatory response. Toll-like receptors are classical pattern-
recognition receptors recognizing both exogenous and host derived ligands. The 
cyanobacterial product CyP is a potent LPS antagonist binding to the TLR4/MD-2 
complex. The aim of the present study was to investigate the role of the 
CD14/TLR4/MD-2 complex in meconium-induced inflammation.  
METHODS 
Whole blood from six donors was preincubated with anti-CD14 or CyP. Meconium 
was added and the samples were incubated for four hours. Twenty-seven 
inflammatory mediators were measured in a Bioplex Array Reader. Human 
embryonic kidney cells transfected with plasmids containing NF-kB dependent 
luciferase reporter, human MD-2, TLR4, TLR2 and/or CD14, were incubated with 
meconium or LPS for 18 hours. Luciferase activity in cytoplasmic extracts was 
measured using a Luciferase Assay System kit. 
RESULTS 
Meconium induced formation of a broad panel of inflammatory mediators. CyP and 
anti-CD14 significantly (p<0.001) inhibited meconium-induced formation of a) 
proinflammatory cytokines (TNF-, IL-1, IL-6, IFN-) by 60-80% and 72-94%, 
respectively, b) anti-inflammatory cytokines (IL-10, IL-1Ra) by 58-59% and 50-65%, 
respectively, c) chemokines (IL-8, MCP-1, MIP-1, MIP-1, eotaxin, IP-10) by 43-
77% and 57-87%, respectively, and d) growth factors (G-CSF, GM-CSF, basic FGF, 
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PDGFbb) by 53-71% and 40-78%, respectively, with no statistical significant 
difference between Cyp and anti-CD14. The inflammatory response could only partly 
be explained by LPS, suggesting that endogenous components of meconium 
contribute to the inflammatory response. Meconium activated NF-kB dose-
dependently in cells expressing TLR4/MD-2 together with CD14, while no effect was 
seen in cells expressing TLR4/MD-2 alone or in TLR2/CD14 transfected cells.  
CONCLUSIONS 
The results indicate that the CD14-dependent meconium-induced inflammatory 
reaction is mediated through the TLR4/MD2 complex. These data may have 
implications for future therapeutic strategies for meconium aspiration syndrome. 
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INTRODUCTION 
Meconium, the first intestinal discharge, represents material accumulated during fetal 
life, like secretions from salivary and intestinal glands like mucus, bile and bile acids, 
fatty acids and steroids from the gut, cellular debris, lanugo hair, components from 
vernix caseosa, amniotic fluid, and blood (Antonowicz and Shwachman, 1979). 
Meconium aspiration syndrome (MAS), a serious disease in newborns including 
aspiration of meconium into the lungs, has a complex, not well defined 
pathophysiology (Cleary and Wiswell, 1998;Dargaville and Copnell, 2006). The 
complement system and Toll-like receptors (TLR), including the CD14-associated 
TLR4/MD-2 complex, are two important components of the innate immune system, 
which both act upstream and partly independently (Uthaisangsook et al., 2002). We 
have earlier shown that meconium is an important activator of complement 
(Castellheim et al., 2004;Mollnes et al., 2008) as well as of  the CD14-mediated 
inflammatory reaction reflected by synthesis of a broad spectrum of cytokines, 
chemokines and growth factors in human whole blood and in cord blood (Salvesen et 
al., 2008). Inhibition of either CD14 or the complement system reduced the 
meconium-induced formation of most inflammatory mediators, but the combined 
inhibition of both systems had a remarkable effect indicating a synergistic effect of 
inhibition of both these two main branches of innate immunity.  
 
The innate immune system recognizes highly conserved structures present on large 
numbers of microorganisms referred to as pathogen-associated molecular patterns 
(PAMPs). These exogenous ligands include bacterial lipopolysaccharide (LPS), 
peptidoglycan, lipotheichoic acids, mannan, zymosan, double stranded RNA, bacterial 
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DNA and glucans (Janeway, Jr. and Medzhitov, 2002). Host-derived 
immunostimulators, i.e. endogenous ligands, like heparan sulphate, hyaluronan, heat-
shock proteins, surfactant proteins, uric acid, fibronectin, -defensin and cardiolipin 
may also signal through the same receptors as PAMPs (Levy et al., 2006;Gay and 
Gangloff, 2007), and was originally termed damage-associated molecular patterns 
(DAMPs) (Seong and Matzinger, 2004;Matzinger, 1994). Recent years DAMP has 
alternatively been used as abbreviation for “danger-associated molecular patterns”, 
covering the general phenomenon of danger signaling of both exogenous and 
endogenous ligands.  
 
Pattern recognition receptors (PRRs) recognize structural patterns on exogenous as 
well as endogenous ligands (Medzhitov and Janeway, Jr., 2000). The classical PRRs 
are the toll-like receptors (TLRs). TLR4, TLR1, 2, and 6 are found on the plasma 
membrane of immune cells and recognize lipoproteins and lipoglycans on the surface 
of microbes. All TLRs except TLR3 signal through the MyD88 pathway leading to 
activation of the NFB gene-transcription program and formation of proinflammatory 
cytokines. TLR4-mediated LPS recognition depend on the protein MD-2, which 
forms a complex with the ectodomain of TLR4 (Shimazu et al., 1999). The 
TLR4/MD-2 complex engages with LPS on cell surfaces via LPS-binding protein 
(LBP) and CD14 (Kawai and Akira, 2009). In addition to being essential for TLR4 
function, the CD14 molecule, but not MD-2, is also involved in the function of TLR2 
(Muta and Takeshige, 2001;Nilsen et al., 2008) and TLR3 (Lee et al., 2006). 
 
The cyanobacterial product (CyP), a LPS-like molecule derived from the 
cyanobacterium Oscillatoria Planktotrix FP1, is a potent and selective antagonist of 
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bacterial LPS in vitro and in vivo by its competitive binding to the TLR4/MD-2-
complex (Macagno et al., 2006).  
 
The aim of the present study was to investigate the role of the TLR4/MD-2 complex 
in meconium-induced inflammation by comparing the effect of MD-2 inhibition by 
CyP with CD14 inhibition in human whole blood and to investigate the involvement 
of CD14, MD-2, TLR4 and TLR2 in human transfected cell lines.   The results 
unequivocally indicate that the CD14-mediated meconium-induced inflammatory 
reaction is mediated through the TLR4/MD-2 complex.   
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METHODS
Reagents and Equipment 
All materials and solutions were endotoxin-free according to the manufacturers. 
Sterile phosphate-buffered saline (PBS) was Dulbecco (Sigma-Aldrich, Oslo, 
Norway). Propylene tubes were NUNC cryotubes (Nalgene NUNC, Roskilde, 
Denmark). Lepirudin (Refludan®) was from Hoechst (Frankfurt am Main, Germany). 
Antibodies and other Reagents 
Mouse anti-human CD14 (clone18D11) was purchased from Diatec (Oslo, Norway). 
CyP
CyP was purified from the freshwater cyanobacterium Oscillatoria planktothrix FP1 
by a phenol-guanidium thiocyanate-based method as described previously (Macagno
et al., 2006). 
Preparation of meconium and the endotoxin assay
Meconium was collected and processed as previously described (Salvesen et al., 
2008). No bacteria were detected after cultivation. The endotoxin or LPS content in 
meconium was analyzed in a Pyrochrome® Limulus Amoebocyte Lysate assay by an 
endpoint chromogenic method using a diazo-coupling assay kit (Associates of CAPE 
COD, Inc., Falmouth, MA). Meconium samples were diluted in depyrogenated 
Pyrotube-D® tubes with LAL Reagent water (both Associates of CAPE COD, Inc., 
Liverpool, UK). The diluted samples were heated to 75C for 10 minutes, mixed with 
pyrochrome solved in Glucashield®, a -glucan inhibiting buffer, and incubated in a 
96-well Pyroplate® (both Associates of CAPE COD, Inc., Falmouth, MA) on a dry 
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block incubator. The assay was performed according to instructions from the 
manufacturer. The LPS content in the meconium was found to be 30EU/mg 
meconium, corresponding to 3ng/mg meconium.
Experimental Set-up 
Titration of CyP 
To investigate the optimal concentration of CyP needed in the following experiments, 
human whole blood anticoagulated with lepirudin at 50μg/mL (Mollnes et al., 2002), 
was collected from two adult healthy donors and distributed into tubes containing 
PBS and CyP, the latter diluted two-fold from 20μg/mL to 0.156μg/mL whole blood. 
The samples were preincubated for five minutes before adding either PBS or a high 
dose of meconium (1mg/mL) (Salvesen et al., 2008). Baseline sample (T0), 
containing only blood and PBS was processed immediately while the other samples 
were incubated for four hours at 37C. Negative control samples after four hours (T4) 
contained blood and PBS. At the end of the incubation ethylenediaminetetraacetic 
acid (EDTA) was added to all samples to a final concentration of 20mM to avoid 
further complement activation. Then the tubes were centrifuged for 15 minutes at 
1400 x g (4C). The plasma samples were stored at -70C until assayed as described 
below. Based on these results a CyP concentration of 20μg/mL was chosen for the 
subsequent meconium experiments. 
Titration of Meconium 
The effect of CyP on cytokine release over a range of meconium concentration was 
then investigated. Human whole blood from two adult healthy donors was collected 
and handled as describe above. The samples were preincubated for five minutes with 
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PBS or CyP 20μg/mL before adding meconium in increasing concentrations (0.003, 
0.01, 0.03, 0.1, 0.3 and 1mg/mL whole blood). Baseline sample (T0), containing only 
blood and PBS was processed immediately while the other samples were incubated 
for four hours at 37C. Negative control samples (T4) contained blood and PBS. At 
the end of the incubation ethylenediaminetetraacetic acid (EDTA) was added to all 
samples to a final concentration of 20mM to avoid further complement activation. 
Then the tubes were centrifuged for 15 minutes at 1400 x g (4C). The plasma 
samples were stored at -70C until assayed as described below. Based on these results 
two different meconium concentrations (0.1 and 1mg/mL whole blood) were chosen 
for the subsequent serial analyses.  
Effect of CyP and anti-CD14 on the meconium-induced inflammatory reaction 
Human whole blood from six adult healthy donors was obtained as described above. 
The samples were distributed into tubes containing PBS, CyP (20μg/mL blood), 
inhibitory anti-CD14 antibody (100g/mL blood), or a negative control (isotype-
matched antibody). The samples were preincubated for five minutes before adding 
either PBS or meconium 0.1 or 1mg/mL whole blood. Baseline sample (T0), 
containing only blood and PBS was processed immediately while the other samples 
were incubated for four hours at 37C. Negative control sample (T4) contained blood 
and PBS. At the end of the incubation ethylenediaminetetraacetic acid (EDTA) was 
added to all samples to a final concentration of 20mM to avoid further complement 
activation. Then the tubes were centrifuged for 15 minutes at 1400 x g (4C). The 
plasma samples were stored at -70C until assayed as described below. Both 
meconium concentrations induced a marked inflammatory response, reflecting the 
dose-response effect observed in the titration studies. The inhibitory effect of CyP and 
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anti-CD14 were similar for both concentrations and the results for meconium 0.1 
mg/mL are presented. 
 
Cytokine Analysis 
The following cytokines, chemokines and growth factors were measured on a Bioplex 
Array Reader (LUMINEX 100, Bio-Rad Laboratories, Hercules, CA) using Bio-Plex 
Human Cytokine 27-plex panel (Bio-Rad Laboratories, Hercules, CA): IL-1Ra, IL-1, 
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, TNF-, 
IFN-, MIP-1, MIP-1, eotaxin, MCP-1, G-CSF, GM-CSF, basic FGF, VEGF, IP-
10, RANTES, and PDGFbb. 
 
Transient transfection and NF-kB Luciferase assay 
This assay has been described in detail previously (Hellerud et al., 2008). Human 
embryonic kidney (HEK) 293 cells (American Type Culture Collection, Manassas, 
VA) were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal calf serum (FCS, Euroclone, Milano, Italy), L-glutamine and 10ug/ml 
ciprofloxacin (Cellgro, Manassas, VA) at 37C and 8% CO2. Transient transfection 
was done using GeneJuiceTM transfection reagent (Novagen, Merck KGaA, 
Darmstadt, Germany) according to the manufacturer’s protocol. In short, cells were 
plated at a cell density of 1x104cells/well in 96-well dishes and grown to 50% 
confluency. Plasmids used were the NF-kB dependent luciferase reporter plasmid 
pELAM-luc (Chow et al., 1999), human CD14 in pcDNA3 kindly provided by Dr. D. 
Golenbock (University of Massachusetts Medical School) , human MD-2 in pEFBOS 
kindly provided by Dr. K. Miyake (University of Tokyo), human TLR4 in pcDNA3 
kindly provided by Drs. R. Medzhitov and C. Janeway (Yale University, New Haven, 
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CT), and human TLR2 in pRK7 kindly provided by Dr. C. Kirschning (Technical 
University of Munich). A dosage of 25ng/well of each plasmid was used for 
transfection and pcDNA3 (Invitrogen Corp., Carlsbad, CA) was used to adjust the 
total amount of plasmid to 100ng/well. All plasmids were isolated using the EndoFree 
plasmid kit (Qiagen Inc., Valencia CA). After transfection for 24 hours, the cells were 
stimulated for 18 hours with meconium (0.01-100μg/mL) or LPS (0.1-1000ng/mL). 
HEK293 cells stably transfected with TLR9 were provided by Eisai Pharmaceuticals 
(Andover, MA). The positive controls were stimulated with 10μM phosphothioate 
CpG DNA 2006 (Tib Molbiol, Berlin, Germany). Cytoplasmic extracts were prepared 
and luciferase activity was measured using the Luciferase Assay System kit according 
to the manufacturer’s recommendations (Promega, Madison, WI) and Victor3TM 1420 
multilabel counter (Perkin Elmer, Waltham, MA). Ultra pure E. coli LPS 0111:B4 
was from ordered from Invivogen (San Diego, CA) and fibroblast stimulating 
lipopeptide (FLS-1) was ordered from EMC Microcollections GMBH (Tübingen, 
Germany).  
Data Presentation and Statistics 
Data from the titration of CyP and meconium (n=2) are presented as mean with range. 
Data from the inhibition experiment with CyP and anti-CD14 (n=6) are presented as 
mean with 95 % confidence interval (CI). Data from the inhibition experiment are 
compared using repeated measurements ANOVA with Tukey as a post test. A two-
tailed p-value below 0.05 was considered significant. Results from the transfection 
cell assay are presented as triplicate (duplicates for TLR9-transfected cells) and are 
given as fold induction relative to the PBS treated control. 
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RESULTS
Dose-dependent effect of CyP on meconium-induced inflammation 
Increasing concentrations of CyP from 0.156- 20μg/mL whole blood dose-
dependently inhibited meconium-induced formation of TNF-, IL-6, IFN-, and IL-8 
(Fig.1). CyP efficiently inhibited the cytokine release even at low doses and 
maximum inhibition was generally reached at 5-10μg/mL. Maximum inhibition for 
IL-8 was reached at 2.5μg/mL and thereafter an apparently slight increase was 
observed.     
Effect of CyP on inflammation induced by different doses of meconium  
Based on the results obtained in the experiments described in Fig.1, a fixed dose of 
CyP (20μg/mL) was used for inhibition experiments using increasing concentrations 
of meconium from 0.003 to 1mg/mL whole blood. A sub-maximal response of 
cytokine release was reached using 0.1mg meconium/mL blood and thereafter a slight 
increase was observed up to 1mg/mL (Fig.2). CyP very efficiently inhibited the 
release of TNF-, IL-1 and IL-6 over the whole range of meconium concentration, 
and markedly reduced the formation of IL-8 although not completely at high 
meconium concentrations.  
Effect of CyP and anti-CD14 on meconium-induced inflammation 
Based on the titration data obtained above, whole blood from six healthy blood donors 
was incubated with meconium at 0.1 and 1mg/mL whole blood and the effect of CyP 
(20μg/mL) and anti-CD14 (100ug/mL) on the cytokine release was investigated. 
Twenty-one of the 27 inflammatory mediators measured were induced by incubation 
with meconium: IL-1Ra, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-15, IL-17, 
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TNF-, IFN-, MIP-1, MIP-1, eotaxin, MCP-1, G-CSF, GM-CSF, basic FGF, IP-
10, and PDGFbb. Data from 16 of these are presented below. Consistent with the 
results presented in Fig.2, there was a modest dose-dependent difference between 
meconium 0.1 and 1mg/mL with respect to the inflammatory response. The effect of 
CyP and anti-CD14 were, however, similar using both doses of meconium. The 
results for meconium 0.1mg/mL are shown below. 
Proinflammatory Cytokines 
The substantial meconium-induced formation of TNF-, IL-1, IL-6, and IFN- was 
significantly reduced by CyP (60-80%) and by anti-CD14 (72-94%) (p< 0.0001 for 
all) (Fig.3, upper four panels). There was no statistical difference between CyP and 
anti-CD14.The same pattern was also found for IL-2, IL-12p70, IL-15 and IL-17 (data 
not shown). 
Anti-inflammatory Cytokines 
The substantial meconium-induced formation of IL-10 and IL-1Ra was significantly 
reduced by CyP (58-59%) and by anti-CD14 (50-65%) (p <0.0001 for all) (Fig.3, 
lower two panels). There was no statistical difference between CyP and anti-CD14. 
The same pattern was also found for IL-4 (data not shown).  
Chemokines
The substantial meconium-induced formation of IL-8, MCP-1, MIP-1, MIP-1, 
eotaxin, and IP-10 was significantly reduced by CyP (43-77%) and anti-CD14 (57-
87%) (p<0.0001 for all) (Fig.4). There was no statistical difference between CyP and 
anti-CD14. 
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Growth Factors 
The substantial meconium-induced formation of G-CSF, GM-CSF, basic FGF, and 
PDGFbb was significantly reduced by CyP (53-71%) and by anti-CD14 (40-78%) 
(p<0.0001 for G-CSF, GM-CSF, basic FGF, p=0.0003 for PDGFbb) (Fig.5). There 
was no statistical difference between CyP and anti-CD14.  
Activation of NF-kB by meconium in transfected HEK293 cells 
Meconium activated NF-kB dose dependently from 1-100ug/ml in HEK293 cells 
expressing TLR4/MD-2 together with CD14, while virtually no response was seen 
when the cells were transfected with TLR4/MD-2 alone (Fig.6, left panel). CD14 
enhanced the efficacy of LPS stimulation at low LPS concentrations, but as the LPS-
concentration increased the effect of CD14 decreased (Fig.6, left panel). The TLR2-
mediated activation of NF-kB by meconium was negligible whether or not CD14 was 
co-expressed (Fig. 6, middle panel), and meconium did not activate NF-kB through 
TLR9 (Fig.6, right panel). No response was seen in cells transfected with NF-kB 
luciferase and empty vector (not shown). 
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DISCUSSION 
In this study we demonstrate for the first time that meconium-induced cytokine, 
chemokine and growth factor formation is mainly mediated through the TLR4/MD-2 
complex as shown by a substantial inhibition of the biomarker release using the LPS 
antagonist CyP. Furthermore, we documented the requirement of CD14 for this 
response using transfected cells.  Thus, the previously observed CD14-dependency of 
meconium-induced cytokine formation (Salvesen et al., 2008) can be attributed to 
signaling via the CD14/TLR4/MD-2 complex. 
 
We have previously shown that meconium induced a potent CD14-mediated 
inflammatory reaction reflected by synthesis of several inflammatory mediators 
(Salvesen et al., 2008) and also activated the second main branch of the innate 
immune system, the complement system, via the lectin and alternative pathways 
(Salvesen et al., 2009;Castellheim et al., 2004;Salvesen et al., 2009) in both cord and 
adult whole blood. A combined inhibition of CD14 and complement in meconium-
induced inflammation showed a remarkable effect on virtually all of the mediators 
measured (Salvesen et al., 2008), indicating a synergistic effect of blocking these two 
main branches of innate immunity on the inflammatory response induced by 
meconium. CyP activates complement dose-dependently from 25μg/mL whole blood 
(Thorgersen et al., 2008). A maximum inhibitory effect of CyP on cytokine formation 
in the present study was obtained at concentrations below 10μg/mL, i.e. below the 
complement activation potential of CyP. IL-8 was most efficiently inhibited at 
2.5μg/mL. Collectively, our data indicate an optimal cytokine-inhibitory effect at CyP 
concentrations of approximately 5μg/mL whole blood.   
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In the present study we investigated the mechanism of the CD14-dependent 
meconium-induced inflammatory reaction. MD-2 is a necessary cofactor for TLR4 in 
the detection of LPS and this process is greatly enhanced by CD14 and LPS-binding 
protein (Perera et al., 1997) (Nagai et al., 2002).  Soluble MD-2 binds LPS directly 
with high affinity and the LPS/MD-2 complex forms a ligand that activates TLR4 
positive cells (Viriyakosol et al., 2000). CyP binds directly to the TLR4/MD-2 
complex and competitively inhibits binding to LPS (Macagno et al., 2006). CyP 
protects mice from lethal LPS-induced shock and exerts its inhibitory activity in 
dendritic cells even if added several hours after LPS.  CyP is a potent antagonist of 
meningococcal LPS (Jemmett et al., 2008) and an efficient inhibitor of E. coli LPS-
induced cytokine release (Thorgersen et al., 2008). In the present study CyP 
decreased the meconium-induced formation of most mediators measured considerably 
and to virtually the same extent as anti-CD14, suggesting that the CD14-dependent 
effect of meconium-induced inflammation is mediated solely through the TLR4/MD-
2 complex.  
 
TLR4 is an important mediator of inflammation and tissue damage (Miyake, 2007). 
Meconium activated NF-kB dose-dependently in HEK293 cells expressing 
TLR4/MD-2 together with CD14, while no response was seen when the cells were 
transfected with TLR4/MD-2 alone. These data indicate that TLR4/MD-2 was not 
only responsible for the CD14 effects, but also completely dependent on CD14 in 
order to induce the cytokine response. LPS is a main exogenous ligand for 
CD14/TLR4/MD-2 and is highly dependent on CD14 (Fitzgerald et al., 2004). 
Endogenous ligands are also candidates for CD14 recognition. Thus, in a recent study 
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by Kaczorowski et al., mice deficient in CD14 showed a significantly lower IL-6 and 
MCP-1 response during cold ischemia/reperfusion injury in the heart (Kaczorowski et 
al., 2009). Our findings indicate that there are substances in meconium that are 
recognized by CD14 before transferred to the TLR4/MD-2 complex. The TLR2-
mediated activation of NF-B was negligible whether or not CD14 was expressed.     
 
Meconium is accumulated in the bowel of the fetus  and is suggested to be sterile 
together with the gastrointestinal tract of the fetus (Mackie et al., 1999).  The 
prevalence of positive amniotic fluid cultures, however, was significantly higher in 
women with meconium-stained amniotic fluid and intact membranes than in women 
with clear fluid (Romero et al., 2006). Jimenez et al identified Enterococcus fecalis in 
17 of 21 meconium samples from healthy newborns and Staphylococcus epidermidis 
in 10 of the samples (Jimenez et al., 2008). Thus, contamination of meconium by 
bacterial products including LPS should be carefully considered. In the present study 
the LPS content of the meconium was 30EU/mg meconium (or 3ng/mg meconium; 
cfr. Methods). We have earlier investigated the role of LPS in meconium-induced 
cytokine formation (Salvesen et al., 2008) by comparing meconium-induced and LPS-
induced cytokine formation in human whole blood. The cytokine formation induced 
by meconium containing 20pg LPS/mg, at 1mg meconium/mL whole blood, was 
considerably higher than that induced by LPS at concentration up to 10ng/mL whole 
blood (Salvesen et al., 2008). In the present study we found a higher LPS content of 
meconium than in the former, most likely reflecting the different LPS-assays used. 
We therefore in the present study also compared LPS and meconium-induced 
proinflammatory cytokine formation in “LPS-equivalent” doses (data not shown). 
There was a dose-dependent increased formation of TNF, IL-1, IL-6 and IL-8 with 
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increasing concentrations of meconium and LPS, respectively, but the meconium-
induced cytokine formation was 5-15 folds higher compared to the increase seen with 
equivalent doses of LPS. The relative difference increased with increasing 
concentrations of meconium. We therefore conclude that LPS, although contributing 
to a certain extent, could not explain the meconium-induced inflammatory reaction. 
Meconium, however, contains innumerable agents which are candidates for 
endogenous danger signaling, in particular since it contains “damaged self”. Cell 
surface TLRs are known to respond to many endogenous ligands like heparan sulfate, 
hyaluronan,  biglycans, fibrinogen, surfactant protein A, fibronectin , HMGB1 and -
defensin (Levy et al., 2006;Miyake, 2007).  We therefore suggest that the 
inflammatory response induced by meconium is mainly mediated by endogenous 
ligands, although the candidate substances are currently unknown.    
 
In the present study meconium induced formation of 21 of 27 mediators measured. 
This is in accordance with our previous study documenting a massive cytokine 
response induced by meconium (Salvesen et al., 2008). The potency of meconium to 
induce an inflammatory reaction is reflected in the clinical picture of MAS which is 
associated both with a chemical pneumonitis and a systemic inflammatory response. 
Notably, many of the inflammatory mediators found in our in vitro study are  the 
same as those measured in neonates with known MAS (Okazaki et al., 2008), 
suggesting that our model is relevant as in vitro model for the inflammatory reaction 
induced in MAS.  
 
Although the incidence of severe MAS has declined in western countries probably 
because of fewer post-term deliveries (Dargaville and Copnell, 2006), MAS is still a 
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severe condition with no specific treatment. The pathophysiology needs further 
investigations. The present study suggests that meconium contains substances that 
activate the TLR4/MD-2 complex mainly by endogenous mechanisms, dependent on 
CD14. The TLR4/MD-2 antagonist CyP reduced meconium-induced inflammation 
almost to the same extent as anti-CD14. Inhibitors of CD14/TLR4/MD-2, including 
CyP, may be therapeutic candidates to attenuate the inflammatory reaction in MAS: 
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FIGURE LEGENDS 
Figure 1 
Dose-dependent effect of CyP on meconium-induced inflammation 
Human whole blood was preincubated with increasing concentrations of CyP from 
0.156 – 20μg/mL blood until meconium 1mg/ mL was added and then incubated for 
four hours. Increasing concentrations of CyP, dose-dependently reduced the 
meconium-induced formation of TNF-, IL-6, IFN- and IL-8. Data are presented as 
means with range from experiments using blood from two different donors. 
Figure 2 
Effect of CyP on inflammation induced by different doses of meconium  
Human whole blood was incubated with increasing concentrations of meconium from 
0.003 to 1mg/mL blood for four hours. Increasing concentrations of meconium, dose-
dependently increased meconium-induced formation of TNF-, IL-1, IL-6 and IL-8 
(closed circles), whereas CyP efficiently reduced this formation (open circles). Data 
are presented as means with range from experiments using blood from two different 
donors.   
Figure 3 
Effect of CyP and anti-CD14 on meconium-induced formation of pro- and anti-
inflammatory cytokines 
Human whole blood preincubated with CyP, anti-CD14 (a14) or an isotype matched 
control antibody (Ctr.) was incubated with meconium (Mec) 0.1mg/mL blood for four 
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hours. B (baseline) = blood incubated for four hours with buffer only. Meconium-
induced formation of the proinflammatory cytokines TNF-, IL-1, IL-6, IFN- and 
the anti-inflammatory cytokines IL-10 and Il-1Ra were measured. Data are presented 
as means with 95% CI of experiments using blood from 6 different donors. * = p < 
0.001 compared with meconium alone. 
Figure 4 
The Effect of CyP and anti-CD14 on meconium-induced inflammation formation 
of chemokines 
Human whole blood preincubated with CyP, anti-CD14 (a14) or an isotype matched 
control antibody (Ctr.) was incubated with meconium (Mec) 0.1mg/mL blood for four 
hours. B (baseline) = blood incubated for four hours with buffer only. Meconium-
induced formation of the chemokines Il-8, MCP-1, MIP-1, MIP-1, eotaxin and IP-
10 were measured. Data are presented as means with 95% CI of experiments using 
blood from 6 different donors. * = p < 0.001 compared with meconium alone. 
 
Figure 5 
The Effect of CyP and aCD14 on meconium-induced inflamation formation of 
growth factors 
Human whole blood preincubated with CyP, anti-CD14 (a14) or an isotype matched 
control antibody (Ctr.) was incubated with meconium (Mec) 0.1mg/mL blood for four 
hours. B (baseline) = blood incubated for four hours with buffer only. Meconium-
induced formation of the growth factors G-CSF, GM-CSF, basic FGF and PDGFbb 
were measured. Data are presented as means with 95% CI of experiments using blood 
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from 6 different donors. * = p < 0.001 compared with meconium alone for G-CSF, 
GM-CSF and basic FGF, and p = 0.003 for PDGFbb. 
Figure 6
Activation of NF-kB by meconium in transfected HEK293 cells   
Relative induction (means and SD) of NF-kB in HEK293 cells transiently transfected 
with NF-kB luciferase and TLR4/MD2 alone or in combination with CD14 (left 
panel), NF-kB luciferase and TLR2 alone or in combination with CD14 (middle 
panel) and NF-kB luciferase and TLR9 (right panel). The highest sample 
concentrations during treatment (10-1 dilution) were 100ug/mL meconium, 1ug/ml 
LPS (positive control for TLR4/MD-2/CD14) and 0.5ug/mL FSL-1 (positive control 
for TLR2/CD14). For TLR9 the cells were treated with 10uM CpG (positive control) 
and 100ug/mL meconium. 
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